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The small ubiquitin-related modifier (SUMO) protein is post-translationally and 
covalently attached to a multitude of other proteins, regulating a plethora of essential 
cellular functions in the nucleus and the cytoplasm. Recent evidence links SUMO to 
membrane-associated functions, however, the mechanism of SUMO regulation at 
membranes remains largely unknown. To look at SUMO regulation, we focused on 
characterizing the subcellular localizations and functions of the SUMO-specific 
isopeptidases, collectively known as SENPs, since they comprise the largest family of 
SUMO proteases and are major regulators of SUMO dynamics. SENPs share a conserved 
C-terminal catalytic domain, but have divergent N-terminal domains containing targeting 
signals that determine their unique subcellular localizations and substrate specificities. In 
this thesis, we characterized the N-terminal domain of the mammalian SUMO-specific 
protease SENP2. We found that SENP2 can directly interact with intracellular 
membranes via a unique N-terminal amphipathic α-helix. We also show that SENP2-
membrane interaction is directly regulated by Karyopherin-α (Kap-α). Furthermore, we 
identified SENP2 interacting proteins using BioID, which revealed that SENP2 interacts 
with a subset of ER-, Golgi-, and inner nuclear membrane-associated proteins. We also 
developed a new technique to identify SENP2 substrates. Collectively, our findings 
demonstrate the critical role N-terminal targeting signals play in the differential 
regulation of SUMO proteases, and indicate that SENP2 may play a role in regulating 
sumoylation at membranes. 
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Post-translational modifications (PTMs) add a level of functional diversity and 
complexity to our proteome. They are inducible and reversible in nature, providing means 
for our cells to rapidly regulate protein activity, localization, and interactions with other 
proteins, nucleic acids, and lipids. PTMs involve the covalent addition of a small protein 
or a functional group onto proteins. Among the many PTMs, one widely studied 
modification is ubiquitination. Ubiquitin is a highly conserved, 76 amino acid protein that 
gets covalently added onto lysine residues of a plethora of other proteins. Although 
ubiquitin is most widely known as a signal for degradation, the complexity and different 
topologies of mono- and poly-ubiquitin chains allow ubiquitin to function as a diverse 
signal and thereby regulate nearly all essential cellular functions, including cell cycle 
progression, chromatin remodeling, and DNA repair (Pickart and Eddins, 2004; 
Hochstrasser, 2009; Tanaka, 2009). Many ubiquitin-like proteins (Ubls) that share a 
similar structural fold with ubiquitin have been identified, including the small ubiquitin-
related modifier SUMO, ISG15, Fat10, NEDD8, and Atg8 (Kerscher et al., 2006). This 
thesis will particularly focus on SUMO and its regulation and potential functions at 
intracellular membranes.  
Our interest in studying SUMO as a post-translational modification stems from its 
wide implications in human health and disease, including 7 diseases that are among the 
top 10 leading causes of death in the U.S. (CDC, 2017). For example, many studies have 
shown that the sumoylation machinery is enhanced in numerous cancers, including 
breast, colorectal, lung, and prostate cancers (Seeler and Dejean, 2017; Yang et al., 
2017). SUMO is also important for proper cardiac development and function, where any 
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misregulation in sumoylation can result in cardiac fibrosis or arrest (Da Silva-Ferrada et 
al., 2016; Liu et al., 2017; Yang et al., 2017). Furthermore, perturbations in neuronal 
sumoylation can contribute to numerous neurodegenerative diseases, including 
Huntington’s, Parkinson’s, and Alzheimer’s disease (Dorval and Fraser, 2006; Guerra de 
Souza et al., 2016; Martins et al., 2016; Ochaba et al., 2016; Yang et al., 2017). 
Collectively, SUMO is involved in every cellular function that is essential for normal 
physiology, and can present a promising therapeutic target for the treatment of many 
diseases. Therefore, understanding the molecular dialogues between SUMO and other 
proteins can unveil the next wave of therapeutics for the advancement of public health.  
 
SUMO AS A DIVERSE SIGNAL 
SUMO is a ~100 amino acid protein that is post-translationally and covalently 
attached to a multitude of other proteins in all eukaryotic cells. It was first discovered as a 
signal that regulates the localization of Ran-GTPase-activating protein RanGAP1. More 
specifically, the sumoylation of RanGAP1 directs its localization to the nuclear pore 
complexes (NPCs) (Matunis et al., 1996; Mahajan et al., 1997). Since then, studies on 
SUMO elucidated other essential roles for this small yet powerful protein. It has been 
shown to be involved in regulating transcription, DNA repair, stress response, 
nucleocytoplasmic trafficking, chromosome segregation, and chromatin remodeling 
(Johnson, 2004; Hay, 2005; Makhnevych et al., 2009). The misregulation of SUMO is 
implicated in a variety of diseases, including cardiac disease, neurodegenerative disease 
and cancers (Yang et al., 2017). Therefore, understanding the molecular mechanisms 
behind SUMO regulation is of crucial importance for the advancement of public health.  
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Yeast and invertebrates express one SUMO, while vertebrates express three 
functional paralogs: SUMO1, SUMO2, and SUMO3. Mammalian SUMO2 and SUMO3 
are 95% identical and are often referred to as SUMO2/3. However, SUMO1 is only 50% 
identical to SUMO2/3 and therefore may have distinct functions. SUMO1 and SUMO2/3 
primarily have unique substrates dictated, in part, by the SUMO conjugation machinery. 
Substrates can be mono-sumoylated, poly-sumoylated, or modified by hybrid SUMO-
ubiquitin chains. Besides ubiquitin, SUMO can also act in combination with other PTMs, 
further diversifying the signaling cascade and downstream biological consequences 
(Saitoh and Hinchey, 2000; Tatham et al., 2001; Johnson, 2004; Guzzo et al., 2012).  
Once a protein is sumoylated, it can interact non-covalently with other proteins 
containing SUMO-interacting motifs (SIMs). A SIM is usually defined as a short 
hydrophobic patch (V/I-X-V/I-V/I) flanked by an acidic patch (Song et al., 2004; Hecker 
et al., 2006; Kerscher, 2007). SUMO-SIM interactions play an important role in defining 
the consequences of sumoylation and can have a variety of effects. First, SUMO-SIM 
interactions enhance protein-protein interactions and can result in the formation of large 
protein complexes. A well-characterized example includes the sumoylation of a known 
tumor suppressor called promyelocytic leukemia protein (PML). In addition to containing 
sites for covalent sumoylation, PML also contains multiple SIMs. Once sumoylated, 
PML binds to other sumoylated PML proteins via its SIMs, thereby forming PML-
nuclear bodies that are able to recruit other sumoylated proteins or proteins containing 
SIMs (Matunis et al., 2006). The SUMO-dependent formation of PML-nuclear bodies 
plays an important role in genome maintenance, stress response, and DNA repair. 
Secondly, SUMO-SIM interactions can facilitate the targeting of sumoylated proteins for 
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proteasomal degradation via the recruitment of SUMO-targeted ubiquitin ligases that 
contain tandem SIMs, like ring finger protein 4 (RNF4). Furthermore, changes in 
structural conformations, or efficient SUMO conjugation can also be facilitated by 
SUMO-SIM interactions (Matunis et al., 2006; Shen et al., 2006; Tatham et al., 2008). 
One example includes the conformational change of thymine DNA glycosylase (TDG). 
TDG enzyme removes mismatched thymine and uracil bases, creating abasic sites in 
double-stranded DNA. The covalent SUMO modification of TDG, and non-covalent 
interactions via SIMs facilitate the conformational change required to release TDG from 
the abasic site, allowing subsequent repair (Hardeland et al., 2002; Baba et al., 2005; 
Steinacher and Schar, 2005; Kerscher, 2007). Collectively, from multiple SUMO 
paralogs, to many unique substrates, to various chain formations and SIMs, sumoylation 
provides a diversity of signals that regulate many essential cellular processes.        
 
THE SUMOYLATION PROCESS – SUMO CONJUGATION AND DE-
CONJUGATION 
The mechanism of SUMO conjugation is closely related to that of ubiquitin, 
involving an ATP-dependent enzymatic cascade of SUMO-specific E1-activating, E2-
conjugating and E3-ligating enzymes (Figure I-1) (Johnson, 2004; Cappadocia and Lima, 
2017). SUMO is initially synthesized as an immature precursor protein that requires 
cleavage by sentrin-specific proteases (SENPs), exposing the di-glycine motif at its C-
terminus (Hickey et al., 2012). The mature form of SUMO can then be activated by the 
ATP-dependent heterodimeric E1 enzyme called Aos1/Uba2. E1 catalyzes the 
adenylation of the C-terminus of SUMO and subsequently forms a thioester linkage 
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between its catalytic cysteine and the C-terminus of SUMO (Johnson et al., 1997). 
Through a transesterification reaction, SUMO is then transferred from E1 to the SUMO-
conjugating enzyme, E2 (Ubc9). Ubc9 can recognize SUMO consensus sites on target 
proteins, which entail a hydrophobic residue (Ψ), an acceptor lysine residue (K) followed 
by any amino acid (X), and ending with an aspartate or a glutamate (Ψ-K-X-D/E) 
(Johnson and Blobel, 1997). Notably, charged Ubc9 can also recognize target proteins via 
their SIM motifs, and facilitate SUMO conjugation on a nearby lysine residue (Johnson, 
2004). Ultimately, Ubc9 mediates the transfer of SUMO to the substrate where the C-
terminal glycine of SUMO covalently binds to the ε-amino group of the acceptor lysine 
residue in the target protein forming an isopeptide linkage (Johnson and Blobel, 1997). 
The E1 and E2 enzymes can catalyze the reaction of SUMO conjugation independently 
from SUMO E3 ligases. However, a number of E3 ligases can contribute to the 
conjugation process, and perhaps more importantly, to substrate selectivity and SUMO 
paralog specificity (Desterro et al., 1997; Johnson and Blobel, 1997; Johnson et al., 1997; 
Li and Hochstrasser, 1999; Bernier-Villamor et al., 2002; Mikolajczyk et al., 2007). 
There are three major classes of SUMO E3 ligases: the protein inhibitor of 
activated STAT (PIAS) family, the vertebrate-specific NPC protein Nup358/RanBP2, 
and the polycomb group member Pc2 (Johnson, 2004; Kerscher et al., 2006). The PIAS 
family is the best-characterized group of E3 ligases. They contain an SP-RING (Siz/PIAS 
RING) domain that is similar to the RING domain of ubiquitin E3 ligases. Yeast encodes 
three PIAS E3 ligases, Siz1, Siz2, and Mms21, while mammals encode five (PIAS1, 
PIAS3, PIASxα, PIASxβ, and PIASy) (Pichler et al., 2002; Kagey et al., 2003; Rytinki et 
al., 2009). While ubiquitin E3 ligases are essential players in determining substrate 
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specificity, SUMO E3 ligases play a peripheral role since they are not required for 
modification. Nevertheless, some SUMO modifications are E3-dependent, a well-
characterized example being the proliferating cell nuclear antigen protein (PCNA) 
(Yunus and Lima, 2009).      
Like other PTMs, the sumoylation process is dynamic and reversible. SUMO de-
conjugation is carried out by a family of SUMO-specific proteases that cleave at the C-
terminus of SUMO (Figure I-1). SUMO proteases not only play a role in de-conjugation, 
but also are required for SUMO precursor maturation, hence directly affecting SUMO 
conjugation (Johnson, 2004; Hickey et al., 2012). The first de-sumoylating enzymes were 
identified in yeast, the ubiquitin-like protease 1 and 2 (Ulp1 and Ulp2) (Li and 
Hochstrasser, 1999, 2003). Later on, six different SUMO-specific proteases were 
discovered in vertebrates, SENP1-3, and SENP5-7 (Table I-1). This class of SUMO 
proteases belongs to the CE class of cysteine proteases, containing a catalytic triad of 
cysteine, aspartate, and histidine (Drag and Salvesen, 2008). All six SENPs share a 
conserved catalytic domain and have divergent N-terminal domains, which are critical in 
determining their respective subcellular localizations (Figure I-2) (Mukhopadhyay and 
Dasso, 2007; Nayak and Muller, 2014). The subcellular localization of SUMO proteases 
greatly influences their substrate specificity. Thus, determining the location of each 
specific protease is a crucial step towards elucidating their function. Table I-1 
summarizes the known subcellular localizations of each protease, their SUMO isoform 
preference, and their generic mode of action (Hickey et al., 2012). Notably, non-classical 
SUMO proteases have also been discovered, including the mammalian DeSI (de-
sumoylating isopeptidase) and USPL1 (ubiquitin-specific peptidase-like protein 1) 
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families, however, their functional significances still remain to be elucidated (Schulz et 
al., 2012; Shin et al., 2012).  
The balance between the rapid SUMO conjugation and de-conjugation is what 
results in the “SUMO enigma” (Hay, 2005); that is, at steady state level, a very low 
percentage of any substrate is found sumoylated, yet that pool of sumoylated substrate 
can have profound functional consequences, demonstrating the power of such a small 
protein modification on the state of the cell.  
 
SUMO REGULATION – A CLOSER LOOK AT SENPs 
All SENPs characterized thus far are essential for survival. This serves as a 
testament for the crucial role SENPs play in regulating the sumoylation pathway. It also 
shows that each SENP plays a distinct, non-redundant role and may be acting on a unique 
subset of sumoylated proteins, subsequently regulating a different set of cellular 
functions. SENP1 and SENP2 for example, regulate cell cycle progression. SENP3 and 
SENP5 are involved in ribosome biogenesis, while SENP6 and SENP7 can edit poly-
SUMO-2/3 chains (Cubenas-Potts et al., 2013; Nayak and Muller, 2014). The question of 
how SENPs recognize different substrates is of major interest in the field. In yeast, it has 
been demonstrated that subcellular localization, dictated by the divergent N-terminal 
domains of Ulp1 and Ulp2, plays a major role in conferring substrate specificity (Li and 
Hochstrasser, 2000). Restricting protease access to a subset of sumoylated proteins could 
be one way to determine which substrates are being regulated, however, it is also possible 
that the divergent N-terminal domains of proteases directly mediate the binding to a 
specific set of substrates. The latter mechanism is yet to be fully investigated.    
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Similarly to yeast, SENPs divergent N-terminal domains also dictate unique 
subcellular localizations in mammals. However, their specific role in defining substrate 
specificity is yet to be fully elucidated. Thus far, SENP1 and SENP2 are known to 
localize at NPCs with the ability to shuttle in and out of the nucleus. SENP3 and SENP5 
localize to the nucleolus, while SENP6 and SENP7 are found in the nucleoplasm (Hang 
and Dasso, 2002; Zhang et al., 2002; Bailey and O'Hare, 2004; Gong and Yeh, 2006; 
Yun et al., 2008). Besides having unique subcellular localizations, SENPs also exhibit 
differences in their enzymatic activities. SENP1 and SENP2 have the highest 
endopeptidase and isopeptidase activity. SENP1 preferentially processes SUMO1 
precursor proteins, while SENP2 processes SUMO2 precursors more efficiently. Both 
SENP1 and SENP2 can deconjugate SUMO1 and SUMO2/3 modified proteins. In 
contrast, SENP3 and SENP5 preferentially deconjugate SUMO2/3, and SENP6 and 
SENP7 function more efficiently as poly-SUMO2/3 chain editors (Mikolajczyk et al., 
2007).  SENP1 and SENP2 are among the best studied SENPs and the two SUMO 
proteases investigated in our lab. 
Although SENP1 and SENP2 both localize to NPCs during interphase, they still 
exhibit divergent, non-redundant functions. This may suggest that their N-terminal 
domains not only contain elements for localization but also contribute to substrate 
specificity by directly binding to sumoylated substrates. Consistent with this, SENP1 
binds to Reptin, a tumor suppressor protein, while SENP2 cannot (Kim et al., 2006). 
Another possibility is that there are other elements or targeting signals at the N-terminus, 
beyond NPC-targeting, that contribute to the regulation and substrate specificity of 
SENP1 and SENP2 but have yet to be discovered. It is also worthy to note that SENP1 
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and SENP2 can be modified by other PTMs, like phosphorylation, that could contribute 
to their divergent functions, localization, and regulation. Also, the presence of multiple 
splice variants with different N-termini increases the regulatory repertoire of SENPs. 
Taken together, it is clear that the diverse N-terminal region of SENPs plays a crucial role 
in determining their specificity and regulation, however, more work is required to 
decipher those differences. This thesis focuses on exploring a novel N-terminal targeting 
signal in SENP2 that may contribute to substrate specificity. 
 
SUMO AT INTRACELLULAR MEMBRANES – THINKING OUTSIDE THE 
NUCLEUS 
Many of the best-studied sumoylated proteins identified thus far localize to the 
nucleus. SUMO is known to play a central role in regulating transcription, DNA repair, 
RNA processing and chromatin remodeling, among many other functions (Johnson, 
2004; Hay, 2013; Hendriks and Vertegaal, 2016). However, there is a rapidly growing 
body of work that provides evidence for SUMO functions outside the nucleus, more 
specifically in the cytoplasm, the endoplasmic reticulum, Golgi, mitochondria, and the 
plasma membrane (Figure I-3). Proteomic analyses, for example, have identified multiple 
non-nuclear targets for sumoylation (Wasik and Filipek, 2014). Additionally, it has been 
well established that the sumoylation machinery is not confined to the nucleus. In fact, 
SENP1 and SENP2 can shuttle in and out of the nucleus (Goeres et al., 2011). Taken 
together, this provides evidence that SUMO has non-nuclear functions that require further 
exploration. 
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The first evidence for SUMO outside the nucleus included the regulation of the 
glucose transporter type 4 (GLUT4) (Giorgino et al., 2000; Sadler et al., 2013). In the 
absence of insulin, only about 1% of GLUT4 is present at the plasma membrane, with the 
majority being localized to GLUT4-storage vesicles (GSVs). It has been shown that 
sumoylation of GLUT4 mediates its sorting and transport to GSVs as well as increases its 
protein expression and stability, showing that SUMO has a direct role in regulating the 
localization and expression of a plasma membrane protein. Another glucose transporter, 
GLUT1, responsible for basal glucose transport, is also sumoylated (Giorgino et al., 
2000; Benson et al., 2017). Biochemical analyses showed that a higher molecular weight 
form of GLUT1 immunopurifies with Ubc9, however, the functional consequences of 
GLUT1 sumoylation needs further characterization. 
Besides its role in directly regulating glucose transport, SUMO has an expansive 
role in regulating ion channels (Benson et al., 2017). To date, at least four ion channels 
have been reported to be sumoylated. The potassium leak channel K2P1 was one of the 
first to be identified as a SUMO substrate. In fact, unlike the majority of sumoylated 
proteins, K2P1 is mostly present in its sumoylated form at the plasma membrane. 
Sumoylation appears to maintain the channel in its inactive form, however, once SUMO 
is de-conjugated, the channel is active and a K+ current is readily detected (Rajan et al., 
2005). This suggests that sumoylation is acutely controlling the function of ion channels 
at the plasma membrane. Other examples include the voltage-gated potassium channels 
Kv1.5 and Kv7.2, both of which are sumoylated. Kv1.5 sumoylation modulates its 
biophysical properties, where any alterations in sumoylation alters the action potential 
duration or the resting membrane potential, subsequently affecting the excitability of 
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atrial myocytes and vascular smooth muscle cells (Benson et al., 2017). Finally, 
sumoylation of the Kv7.2 channel, expressed mainly in the cardiac and nervous systems, 
diminishes the M-current leading to an increased excitability of hippocampal neurons (Qi 
et al., 2014). Together, these reports identify an emerging role for SUMO modification of 
ion channels at the plasma membrane. 
Switching to a different domain, SUMO is also involved in regulating 
mitochondrial functions. The mitochondrion is constantly undergoing cycles of fission 
and fusion, a process that is highly regulated by sumoylation. More specifically, SUMO1 
modification of the dynamin-related protein 1 (Drp1) increases its activity by enhancing 
the binding of Drp1 to the outer mitochondrial membrane, leading to mitochondrial 
fission (Anderson and Blackstone, 2013). Interestingly, and in contrast to SUMO1 
modification, the modification of Drp1 by SUMO2/3 is thought to prevent the protein 
from associating with the mitochondria, thereby inhibiting mitochondrial fission 
(Anderson and Blackstone, 2013). This contrast between SUMO1 and SUMO2/3 
exemplifies how different SUMO paralogs can have different functional outcomes. The 
misregulation of Drp1 sumoylation drastically affects mitochondrial division and is 
associated with brain ischemia, demonstrating the important role SUMO plays in 
regulating mitochondrial function (Fu et al., 2014). 
One common theme that brings together the non-nuclear functions of SUMO, 
from glucose transport to ion channel regulation to mitochondrial division, is that they all 
are membrane-associated functions, which triggers the question: how are membrane-
associated proteins recognized and regulated by the sumoylation machinery? It is 
reasonable to suggest that the sumoylation machinery itself can associate with 
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intracellular membranes, where it directly interacts with membrane-associated proteins 
and regulates their modifications and functions. Consistent with this, fractionation studies 
showed that Ubc9 is found in the plasma membrane fraction (Giorgino et al., 2000), 
however, further studies that characterize the subcellular localization of SUMO E3 
ligases and SENPs is required in order to understand the additional layers of SUMO 
regulation at membranes. Thus far, the SUMO E3 mitochondrial anchored protein ligase 
(MAPL) has been shown to not only associate with the mitochondrial membrane but also 
is the E3 ligase responsible for Drp1 sumoylation (Braschi et al., 2009). Furthermore, 
SENP2, SENP3, and SENP5 overexpression affects Drp1 sumoylation, however, how 
and whether these enzymes are targeted to mitochondria is virtually unknown (Harder et 
al., 2004; Mendler et al., 2016). Of particular interest is the role of SENP2 in regulating 
the sumoylation of the voltage-gated potassium channel Kv7.2. Reduced expression of 
SENP2 in mice results in the hyper-sumoylation of Kv7.2 in hippocampal neurons, 
leading to increased neuronal excitability, seizures and sudden death (Qi et al., 2014). 
Thus, SENP2 is linked to a pathophysiological process involving sumoylation at 
membranes. This raises the intriguing question: does SENP2 directly recognize and 
regulate membrane-associated proteins? This thesis will address in depth the subcellular 
localization of SENP2, particularly at intracellular membranes. 
Adding onto the intracellular membranes theme, several lines of evidence also 
suggest a pivotal role for SUMO modifications in the regulation of inner nuclear 
membrane-associated proteins. For example, emerin and lamin A, major constituents of 
the inner nuclear membrane are both regulated by sumoylation. Importantly, decreased 
sumoylation of lamin A is implicated in familial partial lipodystrophy (FPLD), and 
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familial dilated cardiomyopathy (FDC). Furthermore, sumoylation has been tied with 
chromatin repression and transcriptional regulation, a function that is also related to the 
nuclear membrane (Zhang and Sarge, 2008; Yip et al., 2012; Neyret-Kahn et al., 2013; 
Simon et al., 2013). Collectively, the current data suggests an essential role for SUMO at 
the nuclear periphery. However, the regulation of sumoylation within this domain is 
unclear.  
In summary, SUMO modification is an important and widespread regulatory 
mechanism that is present both in and out of the nucleus, and at intracellular membranes. 
It can have a significant impact on the functions of the cell. Further research is required 
to address SUMO regulation in the cytoplasm, particularly at membranes.  
 
THESIS RATIONALE 
The roles of SUMO in the cell are rapidly expanding. Whether it is in the nucleus 
or in the cytoplasm, almost every essential function in the cell is touched by SUMO. 
Every time a new SUMO substrate is discovered, one begs to ask the question: What 
regulates the regulator? In other words, how is the sumoylation machinery itself being 
regulated? To answer these questions, one must turn to the characterization of important 
master regulators: the SUMO isopeptidases.  
This body of work seeks to answer many questions related to the SUMO 
isopeptidase SENP2 and the regulation of sumoylation at intracellular membranes. Given 
that SENP1 and SENP2 are functionally non-redundant yet are both localized to the 
NPCs, is it possible that there are yet undiscovered targeting signals in their N-terminal 
domains that allow them to be functionally distinguishable? Furthermore, given that 
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SENP2 can directly regulate the voltage-gated potassium channel Kv7.2 (Qi et al., 2014), 
could it be that SENP2 has a targeting signal that allows it to interact with intracellular 
membranes? To answer these questions, I searched for novel targeting signals in the N-
terminal domain of SENP2. Chapter II will discuss how SENP2 is in fact targeted to 
intracellular membranes via a unique N-terminal amphipathic α-helix. Chapter III is 
focused on the development of new and unique tools for identifying and characterizing 
SENP2-specific substrates. Attempting to identify the functional consequences of SENP2 
regulation at intracellular membranes, I have studied multiple potential membrane-
associated protein targets at the inner nuclear membrane, ER, and the plasma membrane, 
which are all described in Appendix I. Overall, our findings illustrate that SENP2 is a 
unique isopeptidase when it comes to regulating the sumoylation of membrane proteins, 














Table I-1. Identified S. cerevisiae and mammalian SUMO proteases. The primary 
location of each SUMO protease, its SUMO isoform preference, and its mode of action, 
is listed.  
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FIGURES AND FIGURE LEGENDS 
Figure I-1. Schematic representation of the SUMO conjugation and de-conjugation 
cycle. SUMO proteases are required for SUMO precursor processing. Mature SUMO is 
then conjugated to substrates through an ATP-dependent enzymatic cascade. E1-
activating enzyme is required for the ATP-dependent activation of SUMO, which is then 
transferred to E2-conjugating enzyme forming a thioester intermediate. SUMO is then 
bound covalently to lysine residues, in an E3 ligase dependent or independent fashion, 
forming an isopeptide linkage. SUMO can have a variety of effects on its substrates, from 
changing enzyme activity, interaction with other proteins, to regulation of protein 
stability. SUMO proteases are responsible for the de-conjugation process.  
18 
Figure I-2. Schematic representation of S. cerevisiae and mammalian SUMO proteases. 
The conserved catalytic domain (CD) is highlighted in grey. N-terminal regions shown to 
be important for subcellular localization of the protease are highlighted in yellow.  
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Figure I-3. Schematic diagram representing the emerging evidence of SUMO functions 
outside the nucleus. The best studied functions of SUMO are associated with the nucleus, 
however, there is emerging evidence for SUMO-mediated regulation of mitochondrial 
fission and fusion, ion channel regulation, insulin secretion, and other non-nuclear 


























Sumoylation regulates a wide range of essential cellular functions, many of which 
are associated with activities in the nucleus. Although there is also emerging evidence for 
the involvement of SUMO at intracellular membranes, the mechanisms by which 
sumoylation is regulated at membranes is largely unexplored. In this study, we report that 
the SUMO-specific isopeptidase, SENP2, uniquely associates with intracellular 
membranes. Using in vivo analyses and in vitro binding assays, we show that SENP2 is 
targeted to intracellular membranes via a predicted N-terminal amphipathic α-helix that 
promotes direct membrane binding. Furthermore, we demonstrate that SENP2 binding to 
intracellular membranes is regulated by interactions with the nuclear import receptor 
karyopherin-α (Kap-α). Consistent with membrane association, BioID revealed 
interactions between SENP2 and ER, Golgi and inner nuclear membrane-associated 
proteins. Collectively, our findings indicate that SENP2 binds to intracellular membranes 
where it interacts with membrane-associated proteins and has the potential to regulate 





The small ubiquitin-related modifier (SUMO) is a highly conserved 100 amino 
acid protein that is post-translationally and covalently attached to a multitude of other 
proteins (Wilson, 2017). Similar to other ubiquitin-like proteins, sumoylation adds 
another level of regulation to protein activity, stability, and localization. Yeast and 
invertebrates express one SUMO protein, while vertebrates express several functional 
paralogs, including SUMO1, SUMO2, and SUMO3. Mammalian SUMO2 and SUMO3 
are 95% identical and thought to be functionally related. However, SUMO1 is only 50% 
identical to SUMO2/3 and may have unique functions (Citro and Chiocca, 2013). The 
mechanism of SUMO conjugation is closely related to ubiquitin. In brief, a SUMO-
activating enzyme (E1) is required for the ATP-dependent activation of SUMO, which is 
then transferred to SUMO-conjugating enzyme (E2) forming a thioester intermediate. 
Ultimately, SUMO is transferred to substrate proteins, in some cases through the action 
of E3 ligases, where its C-terminal glycine is covalently linked to the ε-amino group of 
lysine residues in the target protein forming an isopeptide linkage (Cappadocia and Lima, 
2017). In addition to its action through covalent conjugation, SUMO can also interact 
non-covalently with downstream effector proteins that contain SUMO-interacting motifs 
(SIMs) (Hay, 2013).   
A wide range of essential cellular functions are regulated by sumoylation, many 
of which are associated with activities in the nucleus, including transcription, chromatin 
remodeling and DNA repair (Hendriks and Vertegaal, 2016). However, there is growing 
evidence for the involvement of SUMO in the cytoplasm, most notably at intracellular 
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membranes (Wasik and Filipek, 2014). For example, SUMO plays an important role in 
regulating the dynamin-related GTPase Drp1, which mediates mitochondrial fission once 
recruited to the outer mitochondrial membrane (Anderson and Blackstone, 2013). The 
misregulation of Drp1 sumoylation subsequently affects mitochondrial division and is 
associated with brain ischemia (Fu et al., 2014). Another important SUMO substrate at 
membranes is the cystic fibrosis transmembrane conductance regulator (CFTR). In 
normal conditions, this multi-domain membrane protein resides in the plasma membrane. 
However, the most common mutant form of CFTR associated with cystic fibrosis 
contains a destabilizing phenylalanine deletion at position 508 (ΔF508) that causes the 
protein to be degraded at the ER membrane (Meng et al., 2017). The degradation of 
ΔF508 is mediated by the ubiquitin-proteasome pathway, but has also recently been 
shown to involve sumoylation (Gong et al., 2016). Lastly, sumoylation controls the 
activity of multiple ion channels, including Kv7 potassium channels in hippocampal 
neurons linked to epilepsy and sudden death (Qi et al., 2014).  Despite these and other 
rapidly expanding roles for sumoylation at membranes, what remains to be elucidated is 
how the sumoylation machinery itself is targeted to membranes to control the 
modification of these proteins.    
To investigate SUMO regulation at membranes more closely, we have focused 
our attention on the SUMO de-conjugation machinery. The dynamic and reversible 
nature of sumoylation depends on the action of a variety of SUMO-specific proteases that 
cleave the isopeptide bond formed between the C-terminus of SUMO and its substrates. 
SUMO proteases also mediate SUMO precursor maturation, hence indirectly affecting 
SUMO conjugation. To date, there are three families of structurally distinct SUMO 
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proteases: the SENP (sentrin-specific protease) family, the DeSI (de-sumoylating 
isopeptidase) family, and USPL1 (ubiquitin-specific peptidase-like protein 1) (Nayak and 
Muller, 2014). In mammalian cells, SENPs represent the largest family of SUMO 
proteases, with a total of six encoded SENPs (SENP1-3 and SENP5-7), all of which share 
a conserved C-terminal catalytic domain and variable N-terminal domains (Hickey et al., 
2012). 
The subcellular localization of individual SENPs is determined by distinct 
targeting signals within their N-terminal domains. Consequently, each SENP exhibits a 
unique subcellular localization that is believed to affect function by determining 
accessibility to specific substrates. SENP2, for example, localizes to the nuclear pore 
complexes (NPCs) in interphase and to kinetochores in mitosis (Goeres et al., 2011; 
Cubenas-Potts et al., 2013). SENP2 localization depends on multiple N-terminal 
targeting signals, including a Nup107-160 subcomplex binding domain, and a bipartite 
nuclear localization signal (NLS) that facilitates interactions with karyopherins and FG-
repeat nucleoporins. Disrupting these signals affects not only SENP2 localization but also 
its functions in regulating the sumoylation of kinetochore-associated proteins and 
chromosome segregation in mitosis (Itahana et al., 2006; Goeres et al., 2011; Cubenas-
Potts et al., 2013).  
In addition to its association with NPCs and kinetochores, there is also evidence 
supporting a role for SENP2 in regulating the sumoylation of membrane-associated 
proteins. First, SENP2 regulates the sumoylation of Drp1, hence playing a role in 
mitochondrial fission (Fu et al., 2014). In addition, SENP2 has been implicated in 
controlling the sumoylation of the potassium channel Kv7.2 at the plasma membrane. 
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More specifically, reduced expression of SENP2 in mice results in hyper-sumoylation of 
Kv7.2 in hippocampal neurons, leading to increased neuronal excitability, seizures and 
sudden death (Qi et al., 2014). Thus, SENP2 is linked to pathophysiological processes 
involving sumoylation at membranes. How SENP2 is specifically targeted to protein 
substrates at membranes, however, is unknown.   
In this study, we discovered a new signal within SENP2 that specifies a unique 
subcellular localization to intracellular membranes. We show that SENP2 has a predicted 
amphipathic α-helix at its extreme N-terminus that allows it to directly interact with 
membranes. We also present evidence that the binding of Kap-α to an adjacent NLS 
regulates membrane interaction. Consistent with these findings, we found using BioID 
that SENP2 interacts with a subset of ER, Golgi and inner nuclear membrane-associated 
proteins. Together, our findings have identified SENP2 as a SUMO protease with the 
potential to regulate sumoylation at membranes.   
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MATERIALS AND METHODS 
 
Antibodies 
SENP2 and lamin B rabbit polyclonal antibodies were produced as previously 
described (Chaudhary and Courvalin, 1993; Goeres et al., 2011). Remaining antibodies 
were obtained from the following sources: anti-GFP (Clontech, Mountain View, CA); 
anti-tubulin (Sigma-Aldrich, St. Louis, MO); anti-calnexin (Enzo Life Sciences, Inc., 
Farmingdale, NY); anti-MBP (GenScript, Piscataway, NJ); anti-FLAG M2 (Sigma-
Aldrich, St. Louis, MO); anti-His (Sigma-Aldrich, St. Louis, MO); anti-GM130 (BD 
Biosciences, San Jose, CA); anti-GRP78 (Santa Cruz Biotechnology, Inc., Dallas, TX); 
and mAb414 recognizing p62, Nup153, Nup214, and Nup358 (Abcam, Cambridge, MA). 
 
Plasmid constructs 
SENP2 cDNA was obtained as previously described (Zhang et al., 2002). Full-
length SENP2 and SENP2 deletion constructs (1-63, 143-350, and 10-63) were PCR 
amplified and cloned into pEGFP-C1 as described (Goeres et al., 2011), and cloned into 
pEGFP-N1, using standard cloning procedures. SENP2 NLS mutation (R29A/R49A) 
and/or amphipathic α-helix mutation (I8D) were introduced using PCR based, site-
directed mutagenesis. SENP1 cDNA was a gift from Mary Dasso (National Institute of 
Health, Bethesda, MD). Full-length SENP1 was cloned into pmCherry-C2 vector. MBP 
and MBP-SENP2 fusion proteins, SENP2(1-63)WT and SENP2(1-63)I8D, were cloned into 
a pRSF vector obtained from Jürgen Bosch (Johns Hopkins, Baltimore, MD) for bacterial 
expression. Kap-α2 cDNA was obtained from a mouse fetal liver cDNA library and 
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cloned into pET21a vector (EMD Biosciences, Gibbstown, NJ) as previously described 
(Goeres et al., 2011).  
 
Cell culture, and transfection 
HeLa cells were maintained in DMEM supplemented with 10% fetal bovine 
serum, at 37°C and 5% CO2. Cells were grown at a confluency of 40-50% for 
transfection with the indicated plasmids using Lipofectamine 2000 according to 
manufacturer’s protocol (Invitrogen, Carlsbad, CA). Cells were harvested either at 24 or 




Immunoblot analysis was performed using either enzyme-linked 
chemiluminescence ECL-Prime reagent (GE Healthcare, Silver Spring, MD) and 
developed with film, or using IRDye®-conjugated secondary antibodies and imaged 
using Odyssey infrared imager (LI-COR).  
 
Immunofluorescence microscopy 
HeLa cells were cultured on glass coverslips. Cells were fixed with 2% 
formaldehyde in 1X phosphate-buffered saline (PBS) for 30 minutes at room 
temperature, then permeabilized in 0.2% Triton-X 100 in 1X PBS for 6 minutes at room 
temperature. Immunostaining was carried out as previously described (Matunis et al., 
1996). For ER and Golgi staining, cells were fixed as described above, and then 
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permeabilized using 0.05% digitonin for 6 minutes. Zeiss Observer Z1 fluorescence 
microscope with an Apotome VH optical sectioning grid (Cal Zeiss, Jena, Germany) was 
used to acquire images.  
 
Immunoelectron microscopy 
HeLa cells were processed for indirect immunolabeling of ultrathin cryosections 
essentially as previously described (McCaffery and Farquhar, 1995). Briefly, cells were 
fixed in a monolayer at 4°C in 100mM PO4 (pH 7.4), 2.5% sucrose, and containing 4% 
formaldehyde. The cells were harvested, pelleted and cryo-protected in 2.3M sucrose 
containing 30% polyvinyl pyrollidone. Cell pellets were mounted onto aluminum 
cryopins and frozen in liquid nitrogen. Ultrathin cryosections were then cut on a Leica 
UCT ultramicrotome equipped with an FCS cryostage and sections were collected onto 
300 mesh, formvar/carbon coated nickel grids. Grids were washed, blocked in 10% FCS 
and incubated overnight with primary chicken anti-GFP antibody (10µg/ml). After 
washing, grids were incubated with 6 or 12nm Au-conjugated donkey anti-chicken 
antibody (Jackson ImmunoResearch Labs, Ft. Washington, PA) for 2 hours, washed and 
subsequently embedded in a mixture containing 3.2% polyvinyl alcohol (10,000 MW), 
0.2% methyl cellulose (400 centiposes), and 0.2% uranyl acetate. Sections were analyzed 
on a Tecnai 12 transmission electron microscope and images collected with a Soft 
Imaging System Megaview III digital camera. 
 
Recombinant protein expression and purification 
MBP-tagged SENP2(1-63)WT, SENP2(1-63)I8D, or MBP construct alone were 
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transformed into Escherichia coli Rosetta competent cells. Expression was induced using 
0.5mM isopropylthiogalactoside (IPTG) at 20°C overnight. Cells were pelleted and 
resuspended in ice-cold lysis buffer (50mM Tris-HCl (pH 7.5), 150mM NaCl, 1mM 
EDTA, 1mM phenylmethylsulfonyl fluoride (PMSF), 5mg/ml leupeptin and pepstatin A, 
1mM dithiothreitol (DTT) and 1mg/ml lysozyme). Suspensions were sonicated for a total 
of 1 minute, 0.5-second intervals, and then centrifuged at 30,000 x g for 30 minutes at 
4°C. The supernatant was incubated with equilibrated amylose resin (New England 
Biolabs, Ipswich, MA) for 2 hours at 4°C, with end-to-end rotation. Bound protein was 
eluted in buffer containing 50mM Tris-HCl (pH 7.5), 150mM NaCl, 1mM ETDA, 1mM 
DTT, and 20mM maltose.  
His-tagged mouse Kap-α2 was expressed in Escherichia coli Rosetta competent 
cells as described above and purified using Ni-NTA agarose affinity column 
chromatography, according to manufacturer’s protocol (Qiagen). For expression and 
purification of MBP-SENP2(1-63)WT in complex with His-tagged Kap-α2, both protein 
expression constructs were co-transformed in Escherichia coli Rosetta competent cells. 
Co-expression was induced using 0.5mM IPTG at 20°C overnight. Complex purification 
was performed as described above. A final concentration of 20mM maltose was added to 
co-elute the protein complex.      
 
In vitro liposome co-sedimentation assay 
Lipids dissolved in chloroform, purchased from Avanti Polar Lipids (Alabaster, 
AL), were mixed together in a glass tube to make the following lipid composition: 79 
mol% phosphatidylcholine (PC), 20 mol% phosphatidylethanolamine (PE), and 1 mol% 
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NBD-labeled phosphatidylethanolamine (NBD-PE). Lipid vesicles were prepared 
essentially as previously described (Tu-Sekine and Raben, 2012). Briefly, the 
homogenous lipid mixture was dried under dry nitrogen stream and stored under vacuum 
for 2-20 hours to remove residual chloroform. Lipid films were rehydrated with hydration 
buffer (50mM Tris-HCl (pH 7.5), 150mM NaCl, 1mM EDTA, and 176mM sucrose) at 
37°C for 30 minutes. During hydration, and in 10-minute intervals, samples were 
vortexed and then sonicated in a water bath sonicator for 30 seconds, until the lipid films 
were completely resuspended. Vesicles were formed by extrusion through a 100nm 
polycarbonate membrane, using an Avanti mini-extruder and following manufacturer’s 
protocol. Sucrose-filled liposomes were then diluted with binding buffer (50mM Tris-
HCl (pH 7.5), 150mM NaCl, and 1mM EDTA) at a 1:4 ratio, then spun down at 186,000 
x g in a tabletop ultracentrifuge at 22°C for 1 hour. Pellets were resuspended with 
binding buffer and concentrations were determined using a spectrophotometer. A fresh 
liposomes batch was prepared for each experiment. For liposome co-sedimentation 
assays, 1.5mM, 3mM, 6mM, or 12mM liposomes were mixed with 0.7µg of protein 
prepared in binding buffer, in a total volume of 100µL per reaction. Liposomes and 
protein were incubated for 30 minutes at room temperature. The reaction was pelleted at 
186,000 x g in a tabletop ultracentrifuge at 22°C for 1 hour. Equal volumes of pellet and 
supernatant were analyzed by SDS-PAGE, followed by immunoblotting. It should be 
noted that apparent maximal protein binding varied between individual experiments, but 




Subcellular fractionation  
Isolation of ER membranes was performed as previously described (Bozidis et al., 
2007). Briefly, HeLa cells were seeded in 55cm2 plates and either untreated, or 
transfected with GFP-SENP2(1-63)mNLS or GFP-SENP2(1-63)mNLS/I8D. After 24 hours, 
cells were harvested and pelleted by centrifugation at 200 x g for 10 minutes at 4°C. Cells 
were lysed in 1X MTE buffer (270mM D-mannitol, 10mM Tris-base (pH 7.4), 0.1mM 
EDTA). Lysate was sonicated for a total of 30 seconds, 10-second intervals, and then 
centrifuged at 1400 x g for 15 minutes at 4°C. To separate crude ER from crude 
mitochondria, supernatant was centrifuged at 15,000 x g for 15 minutes. To purify ER 
membranes, supernatant was layered on top of a discontinuous sucrose gradient (from 
bottom to top: 2mL of 2.0M sucrose, 3mL of 1.5M sucrose, 3mL of 1.3M sucrose) in a 
polyallomer ultracentrifuge tube (Beckman Coulter, Indianapolis, IN). ER sucrose 
gradients were centrifuged for 70 minutes at 152,000 x g. Banded ER membranes at the 
1.3M sucrose interface were collected using an 18 Gauge needle then transferred to a new 
polyallomer tube and pelleted at 126,000 x g for 45 minutes. Pellets containing ER 
membranes were resuspended in 1X MTE buffer. Fractions collected were analyzed by 
SDS-PAGE followed by immunoblotting.  
 
Stable cell lines and biotin-streptavidin affinity purification for BioID 
Stable cell lines for BioID analysis were established essentially as previously 
described (Gupta et al., 2015). In brief, the full-length human SENP2 (BC040609) coding 
sequence was amplified by PCR, and cloned into pcDNA5 FRT/TO FLAG-BirA* 
expression vector. Using the Flp-In system (Invitrogen, Carlsbad, CA), 293T-REx Flp-In 
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cells stably expressing FLAG-BirA* alone, FLAG-BirA*-SENP2WT, or FLAG-BirA*-
SENP2I8D were generated. 10 x 150 cm2 plates of sub-confluent (60%) cells were 
incubated for 24 hours in complete media supplemented with 1µg/ml tetracycline (Sigma-
Aldrich, St. Louis, MO) and 50µM biotin (BioShop Canada Inc., Ontario, Canada). Cells 
were collected and pelleted (200 x g, for 3 minutes), the pellet was washed twice with 
PBS, and dried pellets were snap frozen.  
Cell pellets were resuspended in 10mL of lysis buffer (50mM Tris-HCl (pH 7.5), 
150 mM NaCl, 1mM EDTA, 1mM EGTA, 1% Triton X-100, 0.1% SDS, 1:500 protease 
inhibitor cocktail (Sigma-Aldrich, St. Louis, MO), 1:1000 benzonase nuclease 
(Novagen)) and incubated on an end-to-end rotator at 4°C for 1 hour, briefly sonicated to 
disrupt any visible aggregates, then centrifuged at 45,000 x g for 30 minutes at 4°C. 
Supernatant was transferred to a fresh 15mL conical tube. 30µL of packed, pre-
equilibrated streptavidin sepharose beads (GE Healthcare, Silver Spring, MD) were 
added and the mixture incubated for 3 hours at 4°C with end-to-end rotation. Beads were 
pelleted by centrifugation at 2000 x g for 2 minutes and transferred with 1mL of lysis 
buffer to a fresh microcentrifuge tube. Beads were washed once with 1mL lysis buffer 
and twice with 1mL of 50mM ammonium bicarbonate (pH 8.3). Beads were transferred 
in ammonium bicarbonate to a fresh centrifuge tube, and washed two more times with 
1mL ammonium bicarbonate buffer. Tryptic digestion was performed by incubating the 
beads with 1µg MS-grade TPCK trypsin (Promega, Madison, WI) dissolved in 200µL of 
50mM ammonium bicarbonate (pH 8.3) overnight at 37°C. The following morning, 
0.5µg MS-grade TPCK trypsin was added, and beads were incubated 2 additional hours 
at 37°C. Beads were pelleted by centrifugation at 2000 x g for 2 minutes, and the 
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supernatant was transferred to a fresh microcentrifuge tube. Beads were washed twice 
with 150µL of 50mM ammonium bicarbonate, and washes were pooled with the eluate. 
The sample was lyophilized and resuspended in buffer A (0.1% formic acid). 1/5th of the 
sample was analyzed per MS run. 
 
Mass spectrometry 
Analytical columns (75µm inner diameter) and pre-columns (150µm inner 
diameter) were made in-house from fused silica capillary tubing from InnovaQuartz 
(Phoenix, AZ) and packed with 100 Å C18-coated silica particles (Magic, Michrom 
Bioresources, Auburn, CA). Peptides were subjected to liquid chromatography (LC)-
electrospray ionization-tandem mass spectrometry, using a 120-minute reversed-phase 
(100% water–100% acetonitrile, 0.1% formic acid) buffer gradient running at 250ml/min 
on a Proxeon EASY-nLC pump in-line with a hybrid LTQ-Orbitrap Velos mass 
spectrometer (Thermo Fisher Scientific, Waltham, MA). A parent ion scan was 
performed in the Orbitrap using a resolving power of 60,000, then up to the twenty most 
intense peaks were selected for MS/MS (minimum ion count of 1000 for activation), 
using standard collision induced dissociation fragmentation. Fragment ions were detected 
in the LTQ. Dynamic exclusion was activated such that MS/MS of the same m/z (within a 
range of 15 ppm; exclusion list size = 500) detected twice within 15 seconds were 
excluded from analysis for 30 seconds. For protein identification, Thermo .RAW files 
were converted to .mzXML format using Proteowizard (Kessner et al., 2008), then 
searched using X!Tandem (Craig and Beavis, 2004) against the human (Human RefSeq 
Version 45) database. X!Tandem search parameters were: 15ppm parent mass error; 0.4 
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Da fragment mass error; complete modifications, none; cysteine modifications, none; 
potential modifications, +16@M and W, +32@M and W, +42@N-terminus, +1@N and 
Q. Data were analyzed using the trans-proteomic pipeline (Deutsch et al., 2010; Pedrioli, 
2010) via the ProHits software suite (Liu et al., 2010). Proteins identified with a Protein 
Prophet cut-off of 0.9 and at least two unique peptides were analyzed with the SAINT 
express algorithm (v3.6.1) (Teo et al., 2014). Sixteen control runs (consisting of twelve 
FLAG-BirA*only and four samples with no bait expressed) were collapsed to the two 
highest spectral counts for each prey, and the SAINT score cut-off value was set to a 







SENP2 associates with NPCs and with the inner nuclear membrane 
SENP2 has previously been shown to associate with NPCs, based on fluorescence 
microscopy and mass spectrometry-based identification of interacting proteins (Hang and 
Dasso, 2002; Zhang et al., 2002; Goeres et al., 2011). In addition to punctate NPC 
localization, however, we have also observed that SENP2 can be more generally detected 
as a continuous staining of the inner nuclear membrane (Figure II-1). To explore this 
localization more closely, we transiently expressed GFP-SENP2 in HeLa cells and 
examined the co-localization with either mAb414 (a NPC marker) or lamin B (an inner 
nuclear membrane marker). Consistent with previous findings, SENP2 co-localized with 
NPCs, but even more closely co-localized with lamin B (Figure II-1, A and B). We then 
compared the localization of SENP2 with that of SENP1, a second SUMO isopeptidase 
also associated with NPCs (Chow et al., 2012; Cubenas-Potts et al., 2013). Transient co-
transfection of GFP-SENP2 with mCherry-SENP1 showed that SENP2 and SENP1 have 
distinct localization patterns. SENP2 displayed a more continuous staining at the nuclear 
envelope, whereas SENP1 was detected as punctae resembling NPC staining (Figure II-
1C). These results revealed that SENP2 associates with NPCs and also with the inner 
nuclear membrane. To elucidate the molecular basis of SENP2 localization in greater 




The extreme N-terminus of SENP2 contains both NPC and membrane-targeting 
signals 
SENP2 contains multiple N-terminal signals specifying localization, including 
two signals that mediate interactions with NPCs. One signal within amino acids 1-63 
consists of a bipartite NLS that mediates interactions with FG repeat nucleoporins 
through high affinity karyopherin binding. A second signal, within amino acids 143-350, 
interacts with the Nup107-160 subcomplex of the NPC (Goeres et al., 2011). To 
determine whether one or the other of these signals also directs SENP2 to the inner 
nuclear membrane, we closely examined the localization of GFP-tagged fusion proteins 
(Figure II-2). GFP-SENP2(1-63) showed a continuous staining of the inner nuclear 
membrane similar to full-length SENP2 (Figure II-2, A and B). In contrast, GFP-
SENP2(143-350) showed a punctate pattern similar to NPC staining (Figure II-2C). This 
result suggested that the first 63 amino acids of SENP2, in addition to promoting 
interactions with FG-repeat nucleoporins, might also have an additional signal that 
facilitates associations with the inner nuclear membrane. To explore this prediction, we 
deleted the first 9 amino acids and analyzed the localization of GFP-SENP2(10-63) 
(Figure II-2D). Consistent with the presence of a second, membrane targeting signal, 
GFP-SENP2(10-63) was no longer concentrated at the nuclear periphery but instead 
showed a diffuse nucleoplasmic localization. Thus, the extreme N-terminus of SENP2 





The extreme N-terminus of SENP2 contains a predicted amphipathic α-helix 
To explore how residues in the extreme N-terminus of SENP2 may function in 
targeting to the inner nuclear membrane, we performed secondary structure analysis and 
identified a predicted amphipathic α-helix that could serve as an in-plane membrane 
anchor (Figure II-3, A and D). Sequence alignment of the first 52 amino acids of SENP2 
demonstrated that the predicted amphipathic α-helix is highly conserved within mammals 
(Figure II-3B). Interestingly, although the extreme N-terminus of zebrafish SENP2 is not 
conserved at the amino acid sequence level with mammalian SENPs, it nonetheless 
contains a predicted amphipathic α-helix (Figure II-3C). This suggests that the predicted 
amphipathic α-helix has an essential role in the overall function of SENP2. 
To test whether the targeting of SENP2 to the inner nuclear membrane is 
dependent on this predicted amphipathic α-helix, we generated a mutant GFP-SENP2 
expression construct with isoleucine 8 mutated to aspartic acid (I8D) in the hydrophobic 
face of the predicted amphipathic α-helix (Figure II-3D). Wild type or I8D mutant GFP-
SENP2 proteins were transiently expressed in HeLa cells and their localization analyzed 
using fluorescence microscopy. Compared to wild type SENP2, the I8D mutant showed 
reduced targeting to the inner nuclear membrane and enhanced nucleoplasmic 
localization (Figure II-3E, upper panel). The SENP2 I8D mutant retains the 143-350 NPC 
targeting signal, explaining the observed residual membrane localization. To more clearly 
assess the ability of the predicted amphipathic α-helix to target SENP2 to the inner 
nuclear membrane, we evaluated the localization of wild type and I8D mutant GFP-
SENP2(1-63). In contrast to wild type GFP-SENP2(1-63), the I8D mutant showed only 
diffuse nucleoplasmic localization comparable to that observed with GFP-SENP2(10-63) 
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(Figures II-3E and II-2D). These results are consistent with the predicted N-terminal 
amphipathic α-helix acting as an in-plane membrane anchor that tethers SENP2 to the 
inner nuclear membrane.  
 
Overproduction of SENP2 induces the formation of intranuclear membranes 
In addition to localization at the nuclear membrane, GFP-SENP2 is also detected 
in intranuclear foci, whose number and intensity correlate with levels of SENP2 
expression (Figure II-1). Notably, the amphipathic α-helices of several other proteins, 
including Nup153 and Nbp1, form membranous intranuclear inclusions upon 
overexpression (Bastos et al., 1996; Kupke et al., 2011). To investigate whether GFP-
SENP2 overexpression also induces the formation of intranuclear membranes, we 
performed immunoelectron microscopy on ultrathin cryosections of transfected HeLa 
cells (Figure II-4). We found that intranuclear labeling was concentrated within densely 
stained inclusions containing membranous structures reminiscent of those detected in 
cells overexpressing the amphipathic α-helix of Nup153. Cells expressing GFP-SENP2I8D 
did not show similar membranous structures (Figure II-5). These results are consistent 
with interactions between SENP2 and the inner nuclear membrane and suggest an ability 
to stimulate membrane formation.  
 
The N-terminal amphipathic α-helix of SENP2 mediates direct membrane binding 
Although predicted to interact directly with membranes, the N-terminus of 
SENP2 may also promote indirect binding to the inner nuclear membrane through 
interactions with other membrane-associated proteins. To test for direct membrane 
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interaction, we expressed and purified recombinant wild type and I8D mutant SENP2(1-
63) as maltose binding protein (MBP) fusion proteins. The purified proteins were 
incubated with in vitro synthesized liposomes, and membrane binding was evaluated 
using a co-sedimentation assay. Wild type MBP-SENP2(1-63)WT co-sedimented with 
liposomes in a dose-dependent manner, consistent with direct membrane binding (Figure 
II-6, A and C). In contrast, the I8D mutant MBP-SENP2(1-63)I8D did not pellet with 
liposomes, revealing an essential role for the amphipathic α-helix in membrane binding 
(Figure II-6, A and C). As a negative control, liposomes were incubated with purified 
recombinant MBP, which showed no direct membrane interaction (Figure II-6A). As an 
additional control, recombinant proteins failed to sediment in the absence of liposomes 
(Figure II-6B). Thus, our results demonstrate that the predicted N-terminal amphipathic 
α-helix of SENP2 binds directly to membranes. 
 
SENP2 interactions with membranes can be modulated by Kap-α binding 
SENP2 contains a bipartite NLS in close proximity to the predicted N-terminal 
amphipathic α-helix. This NLS binds with high affinity to Kap-α and mediates its import 
to the nucleus and association with FG-repeat nucleoporins (Goeres et al., 2011). Studies 
of other nuclear proteins containing N-terminal amphipathic a-helices in close proximity 
to functional NLSs, including Nbp1, Pom33, and Nup153, have found that karyopherin 
binding inhibits interactions with cytoplasmic membranes prior to delivery to the nucleus 
(Kupke et al., 2011; Floch et al., 2015; Vollmer et al., 2015). To investigate whether 
Kap-α binding similarly controls the membrane interactions of SENP2, we performed 
liposome binding assays in the presence or absence of recombinant purified Kap-α. MBP-
 40 
SENP2(1-63) alone, or in a 1:1 complex with Kap-α-6xHis (Figure II-7D) was incubated 
in the presence or absence of membranes and sedimentation was evaluated by 
centrifugation. As previously observed, ~80% of MBP-SENP2(1-63) co-sedimented with 
liposomes. In contrast, liposome binding of MBP-SENP2(1-63) was reduced by >50% in 
the presence of Kap-α and only ~10% of Kap-α itself associated with the liposome pellet 
(Figure II-7, A and C). Because Kap-α alone has limited membrane affinity (Figure II-8), 
its membrane association in these experiments likely represents levels of MBP-SENP2(1-
63)-Kap-α complexes bound to liposomes. Therefore, levels of Kap-α binding may more 
closely reflect its effects on MBP-SENP2(1-63) membrane interaction. Thus, our results 
reveal that SENP2 membrane interaction can be regulated by Kap-α binding. Next, we 
wanted to investigate Kap-α regulation in an in vivo setting.  
 
Disrupting the SENP2 N-terminal NLS facilitates targeting to cytoplasmic 
membranes  
To investigate the effect of Kap-α binding on SENP2 localization in vivo, we 
analyzed the localization of a mutant GFP-SENP2(1-63) in which the NLS had been 
mutated at two residues (mNLS: R29A/R49A), thereby disrupting the Kap-α interaction 
(Goeres et al., 2011). The effect of this NLS mutation on localization was first analyzed 
by fluorescence microscopy. In contrast to the nuclear membrane localization of GFP-
SENP2(1-63), the NLS mutant protein showed a reticular-like staining pattern in the 
cytoplasm that partially co-localized with the ER marker, calnexin, and co-localized with 
the Golgi marker GM130 (Figure II-9A). To further verify membrane localization in the 
cytoplasm, we isolated a fraction enriched for ER membranes by sucrose gradient 
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sedimentation and performed immunoblot analysis. Consistent with the calnexin co-
localization, GFP-SENP2(1-63)mNLS was detected in the membrane fraction together with 
calnexin (Figure II-9B, left panel). In contrast, when we combined the I8D and NLS 
mutations and performed the same fractionation analysis, we found that GFP-SENP2(1-
63)mNLS/I8D was dramatically reduced in the membrane fraction, and was mostly found in 
the soluble fraction with tubulin (Figure II-9B, right panel). Our findings show that the 
N-terminus of SENP2 has the ability to associate with intracellular membranes in the 
cytoplasm, and this association is negatively regulated by Kap-α binding.   
 
Endogenous SENP2 isoforms associate with intracellular membranes 
Immunoblot analysis of endogenous SENP2 expressed in cultured mammalian 
cells reveals multiple isoforms ranging from 55 to 27 kDa that are thought to be derived 
through alternative splicing. Moreover, endogenous SENP2 is detected at the nuclear 
envelope but also in the nucleus and cytoplasm by immunofluorescence microscopy, 
suggesting differential localization of these isoforms (Goeres et al., 2011). To explore 
possible associations of endogenous SENP2 with membranes, HeLa cells were fixed, 
permeabilized with digitonin and then co-labeled with antibodies recognizing SENP2 and 
the ER protein marker, GRP78 (Figure II-10A). Consistent with ER membrane 
association, the cytoplasmic SENP2 signal co-localized with GRP78. To further validate 
this finding, we again isolated a fraction enriched for ER membranes by sucrose gradient 
sedimentation and performed immunoblot analysis (Figure II-10B). Multiple SENP2 
isoforms migrating at 50, 40 and 27 kDa co-purified with the membrane fraction. 
However, one isoform migrating at ~48 kDa was uniquely detected in the soluble 
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fraction. This isoform may correspond to a splice variant identified in mice that lacks the 
50 N-terminal amino acids, including the predicted amphipathic α-helix (Figure II-10C) 
(Nishida et al., 2001). To investigate whether the co-purification of endogenous SENP2 
isoforms with membranes may be due to interactions with NPCs, we probed fractions 
with mAb414, which recognizes multiple nucleoporins (Figure II-10D). Nup358, 
Nup214, and Nup153 largely co-purified with the soluble fraction, whereas p62 showed 
an equal distribution between soluble and membrane fractions. Thus, although it is 
unlikely that membrane interaction is due to binding to NPC filament proteins, NPC 
binding in general cannot be ruled out.  
 
SENP2 interacts with membrane-associated proteins 
Our results thus far provide evidence that SENP2 associates with the inner nuclear 
membrane, ER, and Golgi membranes. However, the sumoylated proteins regulated by 
SENP2 at these membranes remain largely unknown. We previously used an affinity 
purification-mass spectrometry (AP-MS) based approach to isolate stable SENP2-
interacting proteins and identified proteins of the nuclear pore complex (nucleoporins) 
and soluble nuclear transport receptors (Goeres et al., 2011). In order to identify more 
transiently associated or less abundant SENP2-interacting proteins, including potential 
substrates, we turned to the proximity-dependent biotin identification (BioID) approach 
(Roux et al., 2013). Stable cell lines for inducible expression of full-length wild type 
SENP2 fused to the biotin ligase variant, BirA*, or the BirA* ligase alone were 
generated. Expression levels and localization of FLAG-BirA*-SENP2 were compared to 
endogenous SENP2 via immunofluorescence microscopy and immunoblot analysis 
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(Figure II-11). Following induction, cells were cultured in the presence of biotin for 24 
hours and biotinylated proteins were purified by streptavidin affinity chromatography and 
analyzed by mass spectrometry (a full list of identified proteins can be found in the 
supplemental materials of the following paper: Odeh et al., 2018). This list of proteins 
was analyzed using the Significance Analysis of INTeractomes (SAINT) approach to 
identify high-confidence SENP2-interacting partners (Choi et al., 2012). Consistent with 
previous AP-MS analysis (Goeres et al., 2011), NPC-associated proteins were detected 
(Figure II-12A and supplemental materials in Odeh et al., 2018). Of particular interest, 
and consistent with immunofluorescence microscopy, subcellular fractionation, and in 
vitro binding results, we also detected interactions with proteins of the inner nuclear 
membrane, ER, and Golgi that were not previously identified (Figure II-12A and 
supplemental materials in Odeh et al., 2018). To test whether these unique interactions 
with SENP2 are dependent on its predicted amphipathic α-helix, we performed the BioID 
analysis using stably-expressed FLAG-BirA*-SENP2I8D. Similar to the wild type SENP2, 
SENP2I8D interacted with NPC-associated proteins (Figure II-12B), indicating that these 
interactions are independent on SENP2-membrane association. However, the SENP2I8D 
mutant lost association with most of the membrane-associated proteins compared to the 
wild type protein, consistent with the N-terminal predicted amphipathic α-helix being 
responsible for SENP2-membrane binding (Figure II-12B and supplemental materials in 
Odeh et al., 2018). Given the diffuse nucleoplasmic localization of SENP2I8D, the mutant 
protein also gained new interactions with soluble nuclear proteins that did not interact 





As the functions of SUMO rapidly expand beyond the nucleus, evidence for 
SUMO regulation at multiple intracellular membranes continues to emerge. However, 
very little is known about how SUMO is affecting membrane-associated functions, or 
how sumoylation is regulated at membranes. In this study, we have identified a novel 
interaction between SENP2, an essential regulator of SUMO dynamics, and intracellular 
membranes. We showed that SENP2 has a unique N-terminal amphipathic α-helix, absent 
in other SUMO proteases, which allows it to directly interact with membranes under the 
regulation of Kap-α. We also identified a unique subset of membrane-associated proteins 
that interact with SENP2, providing further insights into the potential roles SUMO can 
play in regulating membrane-associated functions.  
 
SENP2 predicted amphipathic α-helix and membrane interaction 
Our previous study showed that SENP2 associates dynamically with NPCs 
(Goeres et al., 2011). However, our immunofluorescence microscopy data reported here 
indicate that SENP2 not only associates with NPCs, but also co-localizes with the inner 
nuclear membrane. Apparent differences in localization could be explained by GFP-
SENP2 expression levels. At low expression levels, GFP-SENP2 showed punctate 
staining, closely resembling NPC staining. In contrast, the signal for moderate to high 
expression levels of GFP-SENP2 revealed localization to both the NPCs and the nuclear 
membrane (Figure II-13). Thus, SENP2 may have higher affinity for NPCs compared to 
the inner nuclear membrane itself. However, endogenous SENP2 localizes to membranes, 
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including ER and Golgi, evident from subcellular fractionation and colocalization with 
GRP78. We performed colocalization studies with various Golgi marker proteins and 
endogenous SENP2 but were unable to detect obvious Golgi enrichment either due to the 
low level of SENP2 expression or transient interactions between SENP2 and Golgi-
associated proteins and membranes. Nevertheless, consistent with membrane localization, 
in our BioID analysis we identified membrane-associated proteins that interact with 
SENP2 giving us further reason to explore this newly discovered SENP2-membrane 
interaction.   
Sequence analysis and secondary structural predictions revealed that SENP2 has a 
unique N-terminal amphipathic α-helix, absent in other SUMO proteases. Our in vivo and 
in vitro analyses further demonstrated that this predicted amphipathic α-helix directly 
associates with membranes. Studies have shown that there are two classes of amphipathic 
α-helices, one that senses membrane curvature, and one that induces membrane curvature 
(Drin and Antonny, 2010). For instance, proteins with the ArfGAP1 lipid-packing sensor 
(ALPS)-like motif, composed of polar, uncharged residues, mainly serine and threonine, 
are more suitable for sensing membrane curvature (Drin et al., 2007). Examples include: 
the Golgi protein golgin GMAP-210 (Drin et al., 2007), and nucleoporin Nup133 (Drin et 
al., 2007). In contrast, amphipathic α-helices with basic, charged residues are thought to 
induce membrane curvature. Given that SENP2 has a stretch of basic, charged residues 
(refer to Figure II-3D), we predict that its amphipathic α-helix is more suitable for 
inducing membrane curvature, however, further investigation is still required. Notably, 
multiple NPC-associated proteins with ALPS-like motifs (Nup120, Nup85, Nup170, and 
Nup188) or with a basic stretch of amino acids in their amphipathic α-helix (Nup1/Nup60 
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in yeast) have an important role in pore complex insertion into the nuclear membrane 
(Alber et al., 2007; Doucet and Hetzer, 2010; Doucet et al., 2010; Drin and Antonny, 
2010; Meszaros et al., 2015; Souquet and Doye, 2015). SENP2 has also been reported to 
play a role in NPC homeostasis, more specifically, when SENP1 and SENP2 are co-
depleted, the expression levels of certain nucleoporins decreases and are mislocalized 
(Chow et al., 2014). Thus, it would be interesting to explore whether these effects are 
attributed to the ability of SENP2 to bind to membranes through its predicted 
amphipathic α-helix.  
Another aspect of SENP2 that is shared with other proteins with amphipathic α-
helices associated with the inner nuclear membrane, like yeast Nbp1 and Nup1/Nup60 
(Nup153 in humans), is its ability to induce the formation of intranuclear membranes 
upon overexpression (Bastos et al., 1996; Kupke et al., 2011; Meszaros et al., 2015). The 
overexpression of Nup1 for example, results in the de novo synthesis of ‘expansion’ 
membranes that are thought to arise as a secondary response to the physical stress 
imposed on the nuclear envelope (Meszaros et al., 2015). We also noticed the formation 
of intranuclear membranes upon SENP2 overexpression, seen by immuno-EM as arrays 
of membranous structures. Although likely an artifact of overexpression, it is possible 
that the formation of intranuclear membranes is a product of a normal function of SENP2 
amphipathic α-helix and its predicted ability to induce membrane curvature.  
It is interesting to note that Nup1 overexpression results in the enlargement of 
cells indicating a mitotic defect, which was attributed to its amphipathic α-helix and its 
induction of membrane formation (Meszaros et al., 2015). Similarly, it has been 
previously shown that SENP2 overexpression causes cell cycle arrest in mitosis (Zhang et 
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al., 2008). We asked whether this mitotic arrest is dependent on SENP2 amphipathic α-
helix and induction of intranuclear membranes, and we found that the overexpression of 
either SENP2WT or SENP2I8D resulted in a similar mitotic phenotype (Figure II-14). 
Collectively, we found that the SENP2 predicted amphipathic α-helix shares many 
properties with amphipathic α-helices described for other proteins, suggesting important 
consequences for SENP2 function. 
 
SENP2 and Kap-α regulation 
Using in vitro and in vivo methods, we showed that the predicted amphipathic α-
helix of SENP2 is regulated by its interactions with Kap-α. Kap-α binds to the NLS in 
close proximity to the amphipathic α-helix, thereby impeding interactions with 
cytoplasmic membranes. We propose that once SENP2 is transported into the nucleus 
and Kap-α is released, the helix is free to bind to the inner nuclear membrane, hence 
explaining the preferential localization of SENP2 (Figure II-15). Regulation of 
localization has been previously described for other proteins with predicted amphipathic 
α-helices and a proximal NLS, including Nbp1 (Kupke et al., 2011), Nup60 (Meszaros et 
al., 2015), Pom33 (Floch et al., 2015), and Nup153 (Vollmer et al., 2015). Based on our 
findings, we propose that karyopherin binding may serve as a common mechanism to 
regulate the relative distribution of these proteins between nuclear and cytoplasmic 
membranes. 
Kap-α binding to SENP2 could be regulated at multiple levels. First, 
phosphorylation of SENP2 at amino acids within or in close proximity to the NLS could 
regulate the binding of Kap-α. Second, alternative splicing could result in protein variants 
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lacking a functional NLS. Consistent with this latter mechanism, the bipartite NLS of 
SENP2 is split between two exons, exon 1 and exon 2. Collectively, either mechanism 
could explain our detection of endogenous SENP2 at both nuclear and cytoplasmic 
membranes. 
It is also possible that alternative splicing could affect SENP2 localization by the 
presence or absence of the amphipathic α-helix itself. In fact, studies in mice have 
identified an alternatively spliced SENP2 variant lacking the first 50 N-terminal amino 
acids (Nishida et al., 2001). Consistently, we identified two SENP2 variants of ~50kDa 
and ~48kDa that were detected in the membrane and soluble fractions, respectively (refer 
to Figure II-10, B and C). Similar to the SENP2 isoform identified in mice, we predict 
that the lower molecular weight variant lacks the amphipathic α-helix. 
 
Sumoylation at intracellular membranes 
Using BioID, we found that SENP2 interacts with a subset of membrane-
associated proteins in the ER, Golgi and inner nuclear membrane. These interactions are 
dependent on the presence of the predicted amphipathic α-helix. Notably, we did not 
capture those interactions in our previous AP-MS analysis (Goeres et al., 2011), likely 
reflecting the ability of BioID to more effectively capture dynamic, transient protein-
protein interactions (Roux et al., 2013). Since proteins are covalently modified, harsher 
lysis methods can be employed enabling us to identify membrane or poorly soluble 
proteins. Additionally, weak interactors can be retained since protein-protein interactions 
do not have to be maintained post-lysis (Coyaud et al., 2015). One caveat however, is 
that the BioID does not differentiate between SENP2 substrates and interacting proteins. 
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Nonetheless, the interacting proteins that were identified suggest new functions for 
sumoylation at membranes that must be further explored. 
Closer analysis of the functions of the ER- and Golgi-associated proteins 
identified, we found that a significant number of these proteins are involved in vesicle-
mediated transport, for example YKT6, SAR1B, YIF1A, and PREB. Interestingly, 
studies in yeast also showed that SUMO interacts with a subset of proteins involved in 
vesicle transport, suggesting a role for sumoylation in regulating this process 
(Makhnevych et al., 2009). Together, we hypothesize that SENP2 may have a role in 
regulating vesicle-mediated transport, by directly regulating the sumoylation of vesicle 
trafficking proteins.  
In addition to vesicle-mediated transport, sumoylation also plays a role in 
regulating the nuclear export and subsequent translation of mRNAs encoding secreted, or 
membrane-targeted proteins. More specifically, a previous study showed that the SUMO 
E3 ligase, RanBP2/Nup358, located at the cytoplasmic face of the NPC, directly binds 
with the signal sequence coding regions of mRNAs, potentially coupling sumoylation 
with the biogenesis of membrane-targeted proteins (Mahadevan et al., 2013). Given the 
interactions between SENP2 and ER-associated proteins, it will be valuable to explore 
the role of SENP2 in this process.  
It is also worth noting that our BioID analysis identified multiple subunits of the 
ER membrane protein complex (EMC), including EMC1 through EMC5 (also known as 
MMGT1), and EMC7-9 (refer to Figure II-12A). EMC is a multifunctional 10-subunit 
protein complex involved in ER-associated degradation (ERAD), protein folding, cellular 
response to ER stress, lipid homeostasis, and the efficient insertion of tail-anchored 
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proteins into ER membranes (Jonikas et al., 2009; Christianson et al., 2011; Richard et 
al., 2013; Lahiri et al., 2014; Satoh et al., 2015; Wideman, 2015; Guna et al., 2018). 
Since sumoylation is involved in regulating many of the same processes (Enserink, 
2015), it is reasonable to suggest that SENP2 interaction with EMC subunits allows it to 
directly regulate those functions. It is also possible that the EMC complex itself may 
facilitate the binding of the SENP2 amphipathic α-helix to the ER membrane, but this 
requires further investigation.     
Besides ER- and Golgi-associated proteins, a subset of proteins at the inner 
nuclear membrane was also found to interact with SENP2. Among those proteins, lamins 
stood out, as they are well-studied SUMO substrates. Lamin A, for example, is known to 
be sumoylated at several lysine residues: K201, K420, and K486. Multiple mutations 
within the SUMO sites of lamin A result in decreased sumoylation and are associated 
with disease (laminopathies), more specifically, familial dilated cardiomyopathy or 
familial partial lipodystrophy (Zhang and Sarge, 2008; Simon et al., 2013). How the 
sumoylation of lamin A is regulated is still unknown, however, based on the interactions 
we have identified between lamins and SENP2, we suggest that SENP2 may be playing a 
role in regulating the sumoylation process of lamins, particularly lamin A, and therefore 
regulating its functions.  
In conclusion, our study opens doors to further explore the roles of sumoylation at 
membranes. As a crucial next step, SENP2 substrates, including potential candidates 
identified through BioID, need to be further characterized. Overall, our findings further 
illustrate the importance of the unique targeting signals in the N-termini of SENPs and 
their role in defining localization and function. Additionally, based on Kap-α regulation 
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of the amphipathic-α helix, we predict that the N-terminal signals themselves may be 
differentially regulated in response to the physiological needs of the cell.  
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FIGURES AND FIGURE LEGENDS 
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Figure II-1. SENP2 localizes to NPCs and the inner nuclear membrane. HeLa cells were 
transiently transfected with full length GFP-SENP2 and co-localization with NPCs, 
nuclear lamina or mCherry-SENP1 was assessed by fluorescence microscopy. (A) Cells 
were stained with mAb 414, an antibody specific for nucleoporins. GFP-SENP2 partially 
co-localized with the punctate NPC staining. (B) Cells were stained with an antibody 
specific for lamin B, a marker for the inner nuclear membrane. GFP-SENP2 co-localized 
with the continuous lamin B nuclear rim staining. (C) Cells were co-transfected with 
mCherry-SENP1. SENP1 and SENP2 co-localized at NPCs. Continuous rim staining and 

















Figure II-2. The extreme N-terminus of SENP2 directs localization to the inner nuclear 
membrane. HeLa cells were transiently transfected with full length GFP-SENP2 or the 
indicated SENP2 deletion constructs and analyzed by fluorescence microscopy. (A) GFP-
SENP2 localizes to NPCs and the inner nuclear membrane. (B) GFP-SENP2(1-63), 
containing a bi-partite NLS, localizes to NPCs and the inner nuclear membrane similarly 
to full-length SENP2. (C) GFP-SENP2(143-350), containing a nuclear export signal 
(NES) and a signal that binds the Nup107-160 subcomplex of the NPC, localizes only to 
NPCs. (D) GFP-SENP2(10-63) localizes to the nucleoplasm, suggesting the presence of 
an extreme N-terminal signal that targets SENP2 to the inner nuclear membrane. Scale 
















Figure II-3. SENP2 has a predicted amphipathic α-helix at the extreme N-terminus. (A) 
Schematic diagram of full length SENP2. Sequence and structure prediction analyses of 
the first 63 amino acids revealed that SENP2 has a predicted N-terminal amphipathic α-
helix, highlighted in orange and blue. Analysis was performed using the AmphipaseeK 
prediction method (Sapay et al., 2006). (B) Sequence alignment of the first 52 amino 
acids of SENP2. The sequence of the predicted amphipathic α-helix is highly conserved 
among mammals. (C) Amphipathic in-plane membrane anchor predictions of SENP2 in 
human and zebrafish. Lines 1 through 4 show the first 18 amino acid sequence of SENP2, 
membrane topology, secondary structure, and level of amphipathy, respectively. 
Although not conserved at the sequence level, human and zebrafish SENP2 share a 
predicted amphipathic α-helix at the extreme N-terminus. (D) Helical wheel 
representation of the predicted amphipathic α-helix. Orange indicates non-polar residues, 
and blue indicates polar residues. The position of the isoleucine 8 to aspartic acid 
substitution (I8D) is indicated. (E) HeLa cells were transiently transfected with wild type 
(WT) GFP-SENP2, GFP-SENP2(1-63) or the equivalent I8D mutants and analyzed by 
fluorescence microscopy. The I8D mutation resulted in a diffuse nucleoplasmic 
localization and reduced membrane targeting, suggesting that the predicted amphipathic 
α-helix serves as in-plane membrane anchor that tethers SENP2 to the inner nuclear 






Figure II-4. SENP2 overexpression results in the formation of intranuclear membrane 
arrays. HeLa cells were transiently transfected with full length GFP-SENP2 and analyzed 
by immunoelectron microscopy using anti-GFP antibody. Micrographs reveal the 
presence of intra-nuclear membrane arrays upon SENP2 overexpression. Arrows indicate 
the inner nuclear membrane. Scale bar = 200nm.  
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Figure II-5. Overexpression of the mutant GFP-SENP2I8D does not cause the formation 
of intranuclear membranes. HeLa cells were transiently transfected with full length GFP-
SENP2I8D and analyzed by immunoelectron microscopy using anti-GFP antibody. Unlike 
the overexpression of wild type SENP2, the I8D mutant does not induce the formation of 
membranous structures. Arrows indicate the inner nuclear membrane. Scale bar = 500nm.  
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Figure II-6. The N-terminus of SENP2 interacts directly with membranes. (A) 
Recombinant MBP-SENP2(1-63)WT or MBP-SENP2(1-63)I8D were incubated with 
liposomes and membrane binding was evaluated using a co-sedimentation assay. Input, 
pellet and supernatant fractions were analyzed by SDS-PAGE and immunoblotting using
an anti-MBP antibody. MBP-SENP2(1-63)WT co-sedimented with liposomes, whereas the 
I8D mutant and MBP alone did not. (B) Control sedimentation assays were performed in 
the absence of liposomes. Proteins were only detected in the soluble fractions. (C) 
Quantitative analysis from three independent co-sedimentation experiments performed in 
the presence of increasing concentrations of liposomes. MBP-SENP2(1-63)WT bound to 
liposomes in a dose-dependent manner, whereas the I8D mutant showed negligible 
binding even at high liposome concentrations. Error bars indicate standard deviations 
from three independent experiments. 
61 
Figure II-7. SENP2-membrane interaction is inhibited by Kap-!. (A) Recombinant 
MBP-SENP2(1-63) alone, or in a 1:1 complex with Kap-!-6xHis was incubated with 
liposomes and membrane binding was evaluated using a co-sedimentation assay. Input, 
pellet and supernatant fractions were analyzed by SDS-PAGE and immunoblotting using 
anti-MBP and anti-His antibodies. When complexed with Kap-!, SENP2(1-63) 
membrane binding was inhibited. (B) Control sedimentation assays were performed in 
the absence of liposomes. (C) Quantification of SENP2(1-63) liposome binding alone or 
in the presence of Kap-!.  Error bars indicate standard deviations from three independent 
experiments. (D) SDS-PAGE analysis of purified proteins and protein complexes used in 
the liposome co-sedimentation assays.   
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Figure II-8. Kap-! has no membrane binding affinity. Recombinant Kap-!-6xHis was 
incubated in the presence or absence of liposomes, and membrane binding was evaluated 
using a co-sedimentation assay. Input, pellet, and supernatant fractions were analyzed by 
SDS-PAGE and immunoblotting using anti-His antibody. Kap-! showed negligible 
binding to liposomes indicated by the weak signal detected in the pellet fraction. Control 
sedimentation was performed in the absence of liposomes, where Kap-! was only 
detected in the supernatant.  
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Figure II-9. Disrupting the SENP2 N-terminal NLS enables targeting to ER and Golgi 
membranes. Using site-directed mutagenesis, alanine substitutions were generated at 
positions R29 and R49 within the SENP2 N-terminal NLS (designated mNLS) in both 
wild type and I8D GFP-SENP2(1-63) expression constructs. (A) HeLa cells were 
transfected with GFP-SENP2(1-63)mNLS and analyzed by indirect immunofluorescence 
microscopy. Cells were either stained using an anti-calnexin antibody (upper panel) or an 
anti-GM130 antibody (lower panel) to label ER and Golgi membranes, respectively. 
GFP-SENP2(1-63)mNLS partially co-localized with calnexin and co-localized with 
GM130. Scale bar = 5 µm. (B) HeLa cells were transfected with wild type and I8D 
mutant GFP-SENP2(1-63)mNLS and fractions enriched in ER membranes were isolated 
using sucrose gradient sedimentation. Soluble and membrane fractions were analyzed by 
immunoblotting. Tubulin and calnexin were detected as markers for soluble and 
membrane fractions, respectively. GFP-SENP2(1-63)mNLS was concentrated in the 





Figure II-10. Endogenous SENP2 isoforms associate with intracellular membranes. (A) 
HeLa cells were fixed then permeabilized with digitonin. Cells were co-stained with anti-
SENP2 and anti-GRP78 antibodies, and then analyzed by indirect immunofluorescence 
microscopy. Endogenous SENP2 co-localized with GRP78, demonstrating ER membrane 
association. Scale bar = 5µm. (B) HeLa cells were fractionated by sucrose gradient 
sedimentation and fractions enriched in ER membranes were isolated and analyzed by 
immunoblotting. Anti-tubulin and anti-calnexin were used as markers for soluble and 
membrane fractions, respectively. SENP2 isoforms migrating at 50, 40 and 27 kDa were 
found in the membrane fraction. One of the two isoforms migrating at ~48 kDa, both 
indicated by black arrows, was present in the soluble fraction, suggesting the absence of 
the predicted amphipathic α-helix. (C) A schematic diagram representing the two 
potential SENP2 isoforms migrating at ~50 kDa, one lacking the first 50 amino acids. (D) 
Immunoblot using mAb414 showing the distribution of nucleoporins after HeLa cell 
fractionation. Nucleoporin p62 was equally distributed between the soluble and 






Figure II-11. FLAG-BirA*-SENP2WT expression in 293T-REx Flp-In cells. Cells were 
incubated for 24 hours with complete media supplemented with 1µg/ml tetracycline (+ 
TET), or with no tetracycline as a control (- TET). (A) Cells were harvested and stained 
with anti-SENP2 antibody and analyzed by indirect immunofluorescence microscopy. 
Scale bar = 5µm. (B) Cells were harvested and analyzed by immunoblotting. Anti-SENP2 
antibody was used to detect the expression levels of endogenous SENP2 and FLAG-



















Figure II-12. SENP2 interacts with ER, Golgi and inner nuclear membrane-associated 
proteins. SENP2WT or SENP2I8D fused to a promiscuous biotin ligase was stably 
expressed in 293T-REx Flp-In cells. Biotinylated proteins, comprising the pool of SENP2 
interactors, were affinity purified using streptavidin and identified by mass spectrometry. 
(A) Schematic diagram showing SENP2WT interactors. Black arrows indicate previously 
reported SENP2 interactions, and the green arrows indicate newly identified SENP2 
interactions. Proteins were categorized into four broad categories: nuclear envelope 
(including karyopherins, nucleoporins, and inner nuclear membrane), ER membrane, 
ER/Golgi, and Golgi, indicated by pink, blue, green, and yellow circles, respectively. The 
complete list of BioID hits passing SAINT analysis (> 0.75) is provided in the 
supplemental materials of the following paper: Odeh et al., 2018. (B) Volcano plot 
showing the log2 fold change of protein hits identified to interact with SENP2WT vs. 
those interacting with SENP2I8D. Interactors were categorized into four different 
categories: membrane proteins, nuclear pore complex, nucleoplasm, and others/unknown, 
indicated by yellow, red, blue, and grey circles, respectively. The p-value was obtained 
from a t-test comparing a series of four runs between the two baits (SENP2WT and 
SENP2I8D). SENP2I8D lost association with multiple membrane proteins, and gained new 
nucleoplasmic interactors. The complete list of protein hits is provided in the 










Figure II-13. Varying expression levels of GFP-SENP2 could explain the differences in 
SENP2 localization. HeLa cells were transiently transfected with full length GFP-SENP2 
and analyzed by fluorescence microscopy. The punctate staining for GFP-SENP2 in low 
expressing cells resembled NPC staining. Whereas the continuous staining for GFP-
SENP2 in moderate to high expressing cells showed localization to both the NPCs and 




Figure II-14. The overexpression of either SENP2WT or SENP2I8D results in a similar 
mitotic phenotype. HeLa cells were transiently transfected with either GFP-SENP2WT or 
GFP-SENP2I8D mutant. Cells were harvested after 48 hours and analyzed by fluorescence 
microscopy. (A) Cells transfected with either SENP2 constructs experienced mitotic 
arrest, evident from the misalignment of chromosomes during metaphase. Scale bar = 
10µm. (B) Quantitative analysis from two independent experiments showing the relative 
distribution of cells undergoing mitosis. Error bars indicate standard deviations. As 
reported previously, overexpression of SENP2 increases the percentage of cells arrested 
in metaphase (Zhang et al., 2008). This phenotype is not attributed to the amphipathic α-














Figure II-5. Schematic illustrating SENP2 membrane association and regulation by Kap-
! binding. The binding of Kap-! to SENP2 impedes interactions with membranes in the 
cytoplasm. Following protein complex translocation to the nucleus via the import 
machinery Kap-!/", Kap-! is released from SENP2, allowing the amphipathic !-helix to 
associate with the inner nuclear membrane. The binding of Kap-! to SENP2 may also be 
inhibited through unknown mechanisms (?) permitting the amphipathic !-helix to interact 



























The SUMO-specific isopeptidase SENP2 associates with intracellular membranes 
where it interacts directly with membrane-associated proteins. BioID analysis revealed 
interactions between SENP2 and ER, Golgi, and inner nuclear membrane-associated 
proteins. However, whether those proteins are SUMO-modified and substrates of SENP2 
remain uncertain. To assist in further identification of SENP2 substrates, in this study we 
developed a new method called “SUMO capture”, which is dependent on utilizing a 
SENP2 catalytically dead mutant, SENP2CS, in which the catalytic site cysteine residue is 
mutated to serine. By forming a stable complex with sumoylated substrates, it is possible 
to use SENP2CS to enrich for sumoylated proteins recognized and bound by SENP2. We 
performed proof-of-concept experiments to verify the efficiency of the SUMO capture 
technique. We also developed stable cell lines expressing SENP2CS, and optimized co-
immunopurification conditions necessary for subsequent identification of SENP2 
substrates by either immunoblotting or mass spectrometry. Using our approach, we verify 
that LAP2 is a SUMO-modified substrate of SENP2. Collectively, our newly developed 






To investigate the role of SUMO regulation at membranes, in Chapter II we 
focused on characterizing SENP2 and its ability to interact with and potentially regulate 
de-sumoylation at membranes. We discovered a new signal within the N-terminus of 
SENP2, a unique amphipathic α-helix that allows it to directly interact with intracellular 
membranes. We also found using BioID that SENP2 interacts with a subset of ER, Golgi 
and inner nuclear membrane-associated proteins. We showed that these interactions are 
dependent on SENP2 amphipathic α-helix and membrane binding. Taken together, we 
have established that SENP2 may be playing an important role in regulating the many 
functions associated with membrane proteins, however, further investigation is required 
to fully understand the functions of sumoylation and its regulation by SENP2 at 
membranes. To this end, we first need to more definitively identify SUMO-modified 
SENP2 substrates, which is the focus of this chapter.  
Using BioID to identify SENP2 interacting binding partners has the advantage of 
effectively capturing dynamic, transient protein-protein interactions. The covalent biotin 
modification also allows for employing stringent purification methods, which can aid in 
identifying insoluble or membrane-associated proteins (Coyaud et al., 2015). However, 
one caveat with BioID is that it is not possible to distinguish between SENP2 interacting 
proteins and bona-fide SUMO-substrates. Therefore, it is necessary to develop other 
complementary methods to specifically identify SENP2 substrates. In the SUMO field, 
the identification of substrates for a specific SUMO protease is a challenging task for a 
number of reasons. First, sumoylation is a highly dynamic process. The conjugation and 
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de-conjugation cycles are fast reactions, hence a SUMO protease is only transiently 
associated with its substrate for a relatively short period of time. Additionally, as 
mentioned in Chapter I, a very low percentage of any given substrate is present in its 
sumoylated form at steady state level, making it challenging to detect. Very little progress 
has been made to circumvent those challenges in the field, so with that in mind, our goal 
has been to develop a new method that would serve two main purposes: enrich for 
sumoylated proteins, and define SENP2 substrates. 
Our approach to developing a new method takes into account a previously 
established concept: a mutation in the catalytic cysteine of SUMO proteases renders the 
protein inactive by interfering with its de-sumoylation activity (Bailey and O'Hare, 2004; 
Chow et al., 2012). Several studies have suggested that the SENP1 catalytic site mutant 
(C603S) exhibits stable interactions with SUMO-modified proteins. Further evidence, by 
indirect immunofluorescence microscopy, showed that the catalytically dead SENP1CS 
concentrates at foci where SUMO1 is present (Bailey and O'Hare, 2004). The same 
analysis was performed with the wild type protein and no obvious co-localization 
between SUMO1 and SENP1WT was observed. This suggests that SENP1CS stably binds 
and “captures” sumoylated substrates in vivo.  Most importantly, SUMO1 conjugates can 
be co-purified with SENP1CS, suggesting a potentially useful strategy for identifying 
targets of SUMO-specific proteases (Bailey and O'Hare, 2004). Although this evidence 
suggests that SENP1CS can be used to identify SENP1-specific substrates, this method 
has not been developed or utilized, except in few cases mentioned below. Moreover, less 
is known about other SENP catalytically dead mutants and their potential to capture 
sumoylated proteins. SENP1CS was used to identify Elk-1 (E twenty six-like 1) as a 
 79 
substrate of SENP1. Elk-1 is a transcription factor that undergoes rapid de-sumoylation 
following growth factor stimulation, which results in its potent activity as a 
transcriptional activator. Therefore, sumoylation and its regulation by SENP1 play an 
important role in determining Elk-1-dependent transcriptional programs (Witty et al., 
2010). Besides Elk-1, SENP1CS was also utilized to identify a slower migrating band of 
the nucleoporin Nup153 that was confirmed to be sumoylated and therefore regulated by 
SENP1 (Chow et al., 2012). In contrast to SENP1CS utilization, SENP2CS (with a cysteine 
to a serine mutation at amino acid position 548) has only been studied to show that 
SENP2 can regulate the sumoylation of Nup153 (Chow et al., 2012), however, mutant 
characterization and unique substrate identification is lacking.   
In this study, we utilized SENP2CS to capture SUMO at membranes. We also 
present evidence that this method can be used to purify sumoylated substrates for further 
identification. Consistent with our BioID data, and by using SUMO capture, we 
established that the lamin-associated polypeptide 2 (LAP2) is a true SENP2 substrate. 
Together, our findings reveal a new method for the identification of unique substrates of 
SUMO proteases.    
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MATERIALS AND METHODS 
 
Antibodies 
Mouse monoclonal SUMO2/3, and rabbit polyclonal SENP2 and LAP2 antibodies 
were all produced as previously described (Fischer et al., 2001; Zhang et al., 2008; 
Goeres et al., 2011). Remaining antibodies were obtained from the following sources: 
anti-GFP (Clontech, Mountain View, CA); anti-tubulin (Sigma-Aldrich, St. Louis, MO); 
anti-calnexin (Enzo Life Sciences, Inc., Farmingdale, NY); anti-FLAG M2 (Sigma-
Aldrich, St. Louis, MO); anti-ECS (DDDDK) agarose-immobilized (Bethyl Laboratories 
Inc., Montgomery, TX); anti-Myc (Sigma-Aldrich, St. Louis, MO). 
 
Plasmid constructs 
SENP2 cDNA was obtained as previously described (Zhang et al., 2002). Full 
length SENP2 was PCR amplified and cloned into pEGFP-C1 as described (Goeres et al., 
2011), and cloned into pcDNA5 FRT/TO FLAG expression vector, using standard 
cloning procedures. SENP2 NLS mutation (mNLS: R29A/R49A) and/or catalytic 
cysteine mutation (C548S) were introduced using PCR based, site-directed mutagenesis. 
SUMO1 and SUMO2 were cloned into pcDNA3 c-Myc expression vector. 
 
Cell culture, and transfection 
HeLa, 293FT, and 293T-REx Flp-In cells were all maintained and transfected as 
described in the Materials and Methods section of Chapter II.  
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Stable cell lines 
Stable cell lines were established essentially as previously described (Gupta et al., 
2015). In brief, using the Flp-In system (Invitrogen, Carlsbad, CA), 293T-REx Flp-In 
cells stably expressing FLAG alone, FLAG-SENP2WT, FLAG-SENP2mNLS, FLAG-
SENP2CS, or FLAG-SENP2mNLS/CS were generated. Cells were grown to sub-confluency 
(60%) and were incubated for 24 hours in complete media supplemented with 1µg/ml 
tetracycline (Sigma-Aldrich, St. Louis, MO). Cells were collected, pelleted (200 x g, for 
3 minutes) and snap frozen, or immediately resuspended in lysis buffer for further 
analysis.  
 
Immunoblotting, and immunofluorescence microscopy 
Immunoblot and immunofluorescence microscopy analyses were performed as 
described in the Materials and Methods section of Chapter II. 
 
Subcellular fractionation  
Isolation of ER membranes was performed as previously described (Bozidis et al., 
2007), and in the Materials and Methods section of Chapter II.  
 
Co-immunopurification 
For co-immunopurification of FLAG fusion proteins, 293T-REx stable cell lines 
were incubated with tetracycline as described above. Cells were washed with 1X PBS, 
harvested and flash frozen at -80°C or lysed immediately with lysis buffer, recipe 1 
(50mM Tris pH 8.5, 150mM NaCl, 1mM EDTA, 1% Triton X-100) or recipe 2 (50mM 
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HEPES pH 7.4, 100mM KCl, 2mM EDTA, 0.1% NP-40, 10% Glycerol, 1mM DTT). 
Protease inhibitors and 10mM NEM were freshly added. Cells were lysed for 15 minutes 
on ice with gentle shaking then centrifuged at 12,000 x g for 5 minutes. Cleared lysates 
were incubated with anti-FLAG (anti-ECS; DDDDK) agarose-immobilized antibody for 
30 minutes up to 3 hours at 4°C, with gentle end-to-end rotation. An input fraction was 
saved before the incubation with the beads. After incubation, beads were pelleted at 8,200 
x g for 30 seconds and washed at least three times with lysis buffer. Samples were eluted 
with 20µl 2X-sample buffer (125mM Tris HCl pH6.8, 4% SDS, 20% (v/v) glycerol, and 
0.004% bromophenol blue), and then boiled for 3 minutes. Input and IP samples were 






Catalytically dead SENP2 captures sumoylated proteins 
It has been previously shown that mutating the catalytic cysteine to a serine in 
SUMO proteases would render the protease catalytically inactive (Bailey and O'Hare, 
2004; Chow et al., 2012). To show that this mutation can be utilized to specifically 
capture sumoylated proteins recognized by SENP2, we generated a mutant GFP-SENP2 
expression construct with cysteine 548 mutated to serine (CS: C548S). We transiently co-
expressed GFP-tagged wild type SENP2 (SENP2WT) or catalytically dead SENP2 
(SENP2CS) together with Myc-tagged SUMO1 or SUMO2 in HeLa cells (Figure III-1). 
As expected, cells expressing SENP2WT had reduced levels of detectable SUMO 
conjugates, indicating that SUMO was de-conjugated from proteins by SENP2 activity. 
In contrast, cells expressing the catalytically dead mutant SENP2CS had a significant 
increase of sumoylated proteins indicated by a large high molecular weight smear (Figure 
III-1A). Expression of GFP alone was used to indicate the baseline level of global 
sumoylation at steady state.  This result suggests that sumoylated proteins are recognized 
and stabilized by SENP2CS, where the protease binds to its substrate but is incapable of 
de-conjugating SUMO. To further validate this model, we looked at the co-localization of 
GFP-SENP2WT or GFP-SENP2CS with Myc-SUMO by indirect immunofluorescence 
microscopy (Figure III-1B). Consistent with our model, SENP2CS but not SENPWT co-
localized with Myc-SUMO2 at foci around the nuclear periphery and in the nucleoplasm, 
indicating that the catalytically dead mutant is capturing sumoylated proteins. 
Collectively, our results support the idea of utilizing SENP2CS as a tool to capture 
 84 
SUMO-modified substrates.  Next, we wanted to investigate the use of SENP2CS to 
specifically enrich for sumoylated proteins at intracellular membranes.    
 
Catalytically dead SENP2 captures SUMO at membranes 
We have previously established that SENP2 has a predicted amphipathic α-helix 
at its extreme N-terminus that allows it to interact with intracellular membranes and with 
membrane-associated proteins at the ER and Golgi (refer to Chapter II). However, our 
initial studies did not address whether SENP2 interacting proteins represent SUMO-
modified substrates. To test whether we can utilize SENP2CS as a tool to enrich for 
SUMO-modified substrates at membranes in the cytoplasm, we first generated a mutant 
of GFP-SENP2CS in which the NLS had been mutated at two residues (mNLS: 
R29A/R49A), thereby allowing SENP2 to associate with membranes in the cytoplasm 
(SENP2mNLS/CS). We then transiently co-expressed either GFP-SENP2mNLS or GFP-
SENP2mNLS/CS with Myc-SUMO in HeLa cells and analyzed them by 
immunofluorescence microscopy. Consistent with results in SENP2CS-expressing cells, 
SENP2mNLS/CS co-localized with SUMO at foci in the cytoplasm, suggesting an ability to 
capture membrane-associated SUMO substrates (Figure III-2A). To further verify the 
capture of SUMO substrates at membranes, we isolated a fraction enriched with ER 
membranes by sucrose gradient sedimentation and performed immunoblot analysis. 
Consistent with SUMO capture, SUMO conjugates were specifically detected in the 
membrane fraction isolated from cells expressing SENP2mNLS/CS but not SENP2mNLS or 
GFP alone (Figure III-2B). Together, our findings suggest that the catalytically dead 
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mutant of SENP2 can be used to stabilize and capture SUMO-modified proteins in the 
nucleus and at intracellular membranes.     
 
Stable cell lines development and validation 
Our results thus far provide evidence that SENP2CS can be utilized to enrich for 
sumoylated proteins recognized by SENP2. In order to further develop this as a tool to 
purify and identify substrates, we next generated FLAG-tagged constructs of SENP2 and 
tested their transient expression levels and localization in HeLa cells (Figure III-3). 
FLAG-SENP2WT and FLAG-SENP2CS localized to the nuclear periphery, and more 
specifically at the inner nuclear membrane. In contrast, FLAG-SENP2mNLS and FLAG-
SENP2mNLS/CS were concentrated in the cytoplasm as predicted (Figure III-3A). The 
expression levels for each SENP2 protein variant was detected by immunoblotting with 
anti-FLAG antibody (Figure III-3B). Besides HeLa cells, we also tested the transient 
expression of FLAG-SENP2 in other cell lines, including 293FT and 293T-REx Flp-In 
cells, and found that the level of expression of FLAG-SENP2WT and FLAG-SENP2CS 
was comparable to that in HeLa (Figure III-3C). Collectively, our results validate the use 
of these constructs for the development of stable cell lines using 293T-REx Flp-In cells. 
Stable cell lines for inducible expression of full-length wild type SENP2, SENP2CS, 
SENP2mNLS, and SENP2mNLS/CS fused to FLAG were generated and the localization and 
expression levels of SENP2 were validated by indirect immunofluorescence microscopy 
and immunoblotting, respectively (Figure III-4, A and B). Notably, a higher molecular 
weight band, potentially corresponding to a sumoylated form of SENP2, was detected 
with the stably expressing FLAG-SENP2CS cell line (Figure III-4B, upper panel). This 
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suggests that SENP2CS is capable of capturing sumoylated proteins, possibly including its 
own sumoylated form. This result is consistent with previously described observations 
where higher molecular weight bands were detected with SENP1CS and SENP2CS 
overexpression, which were then confirmed to correspond to their sumoylated forms 
(Bailey and O'Hare, 2004; Chow et al., 2012).  
 
The SUMO capture: method development and optimization 
A crucial step in developing the SUMO capture technique is to find the most 
optimal co-immunopurification (Co-IP) conditions that would yield a highly enriched 
fraction of sumoylated proteins. Four different variables were considered for 
optimization: the overexpression of SUMO, lysis buffer and lysis conditions, and 
duration of binding to FLAG beads (Figure III-5). We first evaluated effects of increasing 
overall levels of SUMO-modified proteins on SENP2 pull-downs by transient 
overexpression of SUMO in the stable cell lines (Figure III-5A). We found that there was 
no difference in the levels of sumoylated products captured by SENP2CS with or without 
the overexpression of Myc-SUMO2 (Figure III-6, B, D and E). Therefore, increasing the 
SUMO pool does not necessarily increase the amount of sumoylated products captured 
by SENP2. Additionally, different lysis buffers were tested with or without the addition 
of 10mM N-Ethylmaleimide (NEM), a cysteine protease inhibitor (Figure III-5B). The 
addition of NEM was favorable in our conditions and resulted in a more efficient capture 
of conjugated SUMO, evident from the increase in high molecular weight smear  (Figure 
III-5E). This is likely due to the fact that the active endogenous SENPs can still compete 
with the stably expressed SENP2CS on binding to sumoylated proteins, particularly 
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following lysis and incubation with antibody beads. We also tested three different lysis 
conditions: sonication, gentle shaking at 4°C, or introducing one freeze/thaw cycle and 
found that shaking the samples at 4°C is the most optimal lysis method (Figure III-5C, 
and data not shown). Finally, we tested different incubation times with FLAG beads and 
found that a 30-minute incubation with end-to-end rotation worked better than longer 
durations (Figure III-5, D and E). In summary, different conditions were tested and 
optimized for the Co-IP of sumoylated SENP2 substrates. Next, after Co-IP, we probed 
for potential substrates of SENP2.  
We successfully pulled down SENP2WT and SENP2CS using anti-FLAG beads 
(Figure III-6A), and with our optimized Co-IP conditions, SUMO2/3 co-immunopurified 
with SENP2CS (Figure III-6B). We next wanted to probe for a candidate substrate. We 
chose to probe for LAP2 since it was one of the prominent hits in our BioID analysis. We 
predicted that if LAP2 is sumoylated, it would co-immunopurify with SENP2CS-SUMO 
complex but not with SENP2WT. Consistent with our prediction, and our BioID analysis, 
we identified a higher molecular weight band with SENP2CS expressing cells and using 
anti-LAP2 antibody (Figure III-6C). Given its absence in the FLAG alone and SENP2WT 
cell lines, the higher molecular weight band most likely corresponds to the sumoylated 
form of LAP2. This result provides evidence that our method successfully captured 





In our previous study, we showed that SENP2 uniquely and directly associates 
with intracellular membranes. By using BioID, we identified SENP2 interacting binding 
partners. However, to fully understand the significance of SENP2 at membranes, it is 
important to identify which of those interacting proteins are SENP2-specific substrates. 
In this study, we have developed and tested a new method called “SUMO capture”, 
which utilizes the catalytically dead mutant of SENP2 (SENP2CS). With SUMO capture, 
we showed that we could enrich and identify sumoylated proteins recognized and bound 
by SENP2. SUMO capture is a newly developed tool that can be used to identify unique 
substrates of SUMO proteases.  
 
The SUMO capture: biased and non-biased approaches 
 We developed a Tetracycline-inducible (TET-inducible) cell line stably 
expressing FLAG-SENP2CS, and provided evidence that we can pull-down, or capture, 
sumoylated proteins by FLAG Co-IP. Following FLAG Co-IP, we identified LAP2 as a 
substrate of SENP2 by immunoblotting using anti-LAP2 antibody. This targeted, or 
biased, approach was made possible by our previously published BioID data (Odeh et al., 
2018). LAP2 was previously identified as a SENP2 interacting partner and using our new 
SUMO capture technique followed by immunoblotting, we confirmed LAP2 as a SENP2 
substrate. We are also interested in identifying other SENP2 substrates by taking a non-
biased approach, as this will provide us with a comprehensive catalog of unique 
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substrates. The non-biased approach would entail identification of co-purifying proteins 
by mass spectrometry, which is currently underway.  
 
LAP2 as a substrate of SENP2 
Using SUMO capture, we identified LAP2 as a substrate of SENP2. The LAP2 
gene (also known as thymopoietin, or TMPO) encodes six spliced isoforms. Of those, we 
can at least detect three isoforms by western blotting: α, β, and γ. With the exception of 
LAP2α, all isoforms share a similar C-terminal transmembrane domain that allows for 
direct interaction with the inner nuclear membrane. All of LAP2 proteins play a role in 
lamina organization, and maintenance of nuclear growth and integrity (Gant et al., 1999). 
From previous mass spectrometry-based analyses, LAP2 was identified as a SUMO 
substrate (Tammsalu et al., 2014; Hendriks et al., 2015). However, those findings were 
not further validated. Given the predicted size of LAP2β, and consistent with the fact that 
SENP2 also interacts with the inner nuclear membrane, the higher molecular weight band 
that was observed in our SUMO capture likely corresponds to LAP2β protein. How 
sumoylation and SENP2 regulation affects LAP2β function is still a question that needs 
to be further investigated, however, we speculate that the sumoylation of LAP2β 
regulates its localization and function at the inner nuclear membrane. 
 
The SUMO capture: pros & cons 
We developed SUMO capture to address major challenges in the SUMO field: the 
transient nature of sumoylation, and the resulting low, steady state abundance of 
sumoylated proteins. While we were successfully able to tackle both issues with SUMO 
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capture, our pull-downs were not efficient. The input and IP samples showed comparable 
amounts of FLAG-SENP2 (refer to Figure III-6A), meaning that the 10% of IP sample 
loaded is only about 20ug of FLAG-SENP2 protein. Since our total input in each IP was 
about 4-5mg, it appears that only a small fraction of total protein is being pulled down. 
This inefficiency could be attributed to multiple issues. The FLAG-SENP2 plasmid 
constructs used for generating the stable cell lines were designed with a single FLAG, 
and the detection of FLAG-SENP2 with anti-FLAG antibody was very inefficient (refer 
to Figure III-4B). This could be due to epitope masking, which could also explain the low 
level of binding of FLAG-SENP2 to agarose-immobilized anti-FLAG antibody during 
immunopurification. Based on evidence from the current literature, one way to 
circumvent this issue would be to add tandem FLAG tags (at least 3X FLAG) to the 
construct, or to use a different tag. It has also been suggested that the FLAG tag itself can 
be modified when expressed in certain cell lines, including 293T cells, contributing to 
epitope masking (Schmidt et al., 2012). Therefore, changing the cell line could be taken 
into consideration.  Another reason that could add to the pull-down inefficiency is the on 
and off rate of SENP2CS-bound substrates. The SENP2CS-SUMO complex might be 
dissociating during lysis, binding, or Co-IP steps, making the conjugated SUMO 
available for active endogenous SENPs. NEM was added to the lysis buffer to inhibit the 
activity of endogenous SENPs, however, developing the stable cell line in a SENP2 
knockdown background, or alternatively, light crosslinking between SENP2CS and its 
sumoylated substrate might be helpful. Finally, we have observed a higher molecular 
weight band co-immunopurifying with SENP2CS, most likely corresponding to the 
sumoylated form of SENP2, as described previously (Bailey and O'Hare, 2004; Chow et 
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al., 2012). One could predict that since the catalytic cysteine is mutated to a serine, when 
cysteine and serine proteases have similar mechanism of action, an intermediate is 
forming between SUMO and the catalytic mutant that would account for the shift in 
weight (Bailey and O'Hare, 2004). However, the same higher molecular weight band is 
observed when the catalytic cysteine is mutated to an alanine, ruling out the possibility of 
an intermediate and reinforcing that the shifted band corresponds to a modified form of 
the inactive enzyme (Bailey and O'Hare, 2004). Collectively, this raises the concern that 
SENP2CS might favor capturing its own sumoylated form rather than other sumoylated 
substrates. To better capture sumoylated proteins, the identification and mutation of the 
sumoylated SENP2 residue might be important. 
Although we discuss here a few challenges with SUMO capture efficiency, we are 
confident that this method can be further optimized for the successful identification of 
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Figure III-1. The SUMO capture: proof-of-concept. HeLa cells were transiently co-
transfected with Myc-SUMO and either GFP alone, GFP-SENP2WT, or GFP-SENP2CS 
for 24 hours. Cells were then harvested and analyzed by immunoblotting and indirect 
immunofluorescence microscopy. (A) Immunoblotting using anti-Myc showed that GFP-
SENP2CS can enrich for the conjugated SUMO pool, compared to GFP alone or 
SENP2WT. Anti-GFP antibody was used to detect the expression levels of each GFP-
tagged construct, and anti-tubulin was used as a loading control. (B) Cells were stained 
with anti-Myc antibody and analyzed by indirect immunofluorescence microscopy. 
Consistent with the immunoblotting results, Myc-SUMO showed clear co-localization 
with GFP-SENP2CS at foci within the nucleus and the nuclear periphery. No clear co-
localization was detected with GFP-SENP2WT, suggesting that SUMO is being trapped at 
locations where the catalytically dead SENP2 is present but not the WT protein. Scale bar 












Figure III-2. Catalytically dead SENP2 captures SUMO at membranes in the cytoplasm. 
HeLa cells were transiently co-transfected with Myc-SUMO2 and either GFP, GFP-
SENP2mNLS, or GFP-SENP2mNLS/CS for 24 hours. (A) Cells were harvested, permeabilized 
with digitonin, and stained with anti-Myc antibody and analyzed by indirect 
immunofluorescence microscopy. SUMO only co-localized with GFP-SENP2mNLS/CS in 
foci at cytoplasmic membranes. No apparent co-localization was observed with SUMO 
and SENP2mNLS. Scale bar = 5 µm. (B) HeLa cells were harvested 24 hours post-
transfection and fractions enriched in ER membranes were isolated using sucrose 
gradient sedimentation. Soluble and membrane fractions were analyzed by 
immunoblotting. Tubulin and calnexin were detected as markers for soluble and 
membrane fractions, respectively. A fraction of tubulin protein was present in the 
membrane fraction, indicating an impure fraction, however, the trends of capturing 
SUMO at membranes still hold true. Both GFP-SENP2 constructs were concentrated in 
the membrane fraction, whereas GFP alone, used as a control, was soluble (not shown). 
SUMO2 was enriched with GFP-SENP2mNLS/CS in the membrane fraction when compared 
to control cells transfected with GFP alone. Given that GFP-SENP2 constructs were not 
found in the soluble fraction, no differences were observed in SUMO2 enrichment 







Figure III-3. Validation of newly generated FLAG-SENP2 constructs. Cells were 
transiently transfected with FLAG-SENP2 to validate the protein expression and 
localization of each SENP2 variant (WT, mNLS, CS, and mNLS/CS). Cells were 
harvested after 24 hours and analyzed by indirect immunofluorescence microscopy and 
immunoblotting. (A) HeLa cells were fixed and stained with anti-FLAG antibody. 
SENP2WT and SENP2CS are localized at the nuclear rim, more specifically at the inner 
nuclear membrane. SENP2mNLS and SENP2mNLS/CS are in the cytoplasm, mostly at 
intracellular membranes (ER and Golgi), as expected. Scale bar = 5 µm. (B) Validation of 
the expression levels of each overexpressed SENP2 variant in HeLa cells by 
immunoblotting. Anti-FLAG antibody was used to detect FLAG-SENP2. Tubulin was 
used as a loading control.  
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Figure III-4. FLAG alone or FLAG-SENP2 expression in 293T-REx Flp-In cells. Cells 
were incubated for 24 hours with complete media supplemented with 1µg/ml TET, or 
with no TET as a control. (A) Cells supplemented with TET were harvested and stained 
with anti-SENP2 antibody and analyzed by indirect immunofluorescence microscopy. 
Scale bar = 10 µm. (B) Cells were harvested and analyzed by immunoblotting. Anti-
SENP2 was used to detect the expression levels of FLAG-SENP2, indicated by an arrow. 
Lower molecular weight bands represent endogenous SENP2. A potentially sumoylated 
form of SENP2 is detected with FLAG-SENP2CS, indicated by an asterisk (*). FLAG-
SENP2 can be detected using anti-FLAG antibody, however, the signal is weak. Tubulin 
was used as a loading control.  
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Figure III-5. FLAG Co-IP conditions: method development and optimization. Schematic 
diagram illustrating the different conditions that were tested to find the most optimal 
conditions to enrich for sumoylated, SENP2-dependent substrates. (A) 293T-REx cells 
stably expressing FLAG-SENP2 upon TET induction were transiently transfected with 
Myc-SUMO2 for 24 hours or kept non-transfected. (B) Cells were harvested in either 
buffer recipes indicated, with or without the presence of 10mM NEM (cysteine protease 
inhibitor). (C) Cell lysis was carried out either by sonication, 15 minute gentle shaking at 
4C, or by one freeze/thaw cycle. (D) Cell lysates were incubated with agarose 
immobilized anti-FLAG (anti-ECS, DDDDK) antibody for the time indicated, at 4C with 
gentle end-to-end rotation. The most optimal conditions tested are highlighted in green. 
(E) Immunoblot showing the optimization results. The addition of 10mM NEM to the 
lysis buffer stabilizes the conjugated form of SUMO. Cell lysates were incubated with 
antibody beads for the indicated amount of time (2 hours, 1 hour, or 30 minutes). A 30-












Figure III-6. Co-IP of FLAG-SENP2 and potential sumoylated substrates. (A-C) Stable 
cell lines expressing FLAG alone, FLAG-SENP2WT, or FLAG-SENP2CS were harvested 
after TET induction for 24 hours. Cells were lysed and incubated with agarose 
immobilized anti-FLAG antibody for 1 hour, and FLAG-SENP2 and associated proteins 
were eluted and analyzed by immunoblotting. (A) anti-SENP2 antibody was used to 
detect FLAG-SENP2 in the input and IP samples. A potentially sumoylated form of 
SENP2 is indicated by an asterisk (*). (B) anti-SUMO2/3 antibody was used to detect the 
amount of sumoylated proteins that are pulled down with FLAG-SENP2. (C) Multiple 
LAP2 isoforms are recognized by LAP2 antibody. Indicated by an arrow is a potentially 
sumoylated form of LAP2β, and is exclusively pulled down with the catalytically dead 
mutant SENP2CS suggesting that LAP2β is a confirmed substrate of SENP2. (D-F) Stable 
cell lines were transiently transfected with Myc-SUMO2 to increase the sumoylated pool 
of proteins and then were harvested and analyzed as described above. (D) and (E) anti-
Myc and anti-SUMO2/3 antibodies were used to detect Myc-SUMO2 in the input and 
FLAG IP samples. There is an increase in the pool of sumoylated proteins, however, the 
amount of sumoylated proteins pulled down after IP are not significantly higher relative 
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We have established that SENP2 directly interacts with intracellular membranes 
via a unique amphipathic α-helix (refer to Chapter II). We also showed that SENP2 
associates with a subset of membrane-associated proteins at the ER, Golgi, and inner 
nuclear membranes, and have developed methods to identify unique SENP2 substrates 
(refer to Chapter II and III). Though the questions still remain: Why is SENP2 at 
membranes? What is the functional significance of SENP2 regulation through targeted 
localization? In this appendix, we present several approaches to address these questions. 
Our BioID analysis revealed that SENP2 interacts with proteins involved in ER-
to-Golgi trafficking, ER biogenesis, and protein quality control. SENP2 interactors at the 
inner nuclear membrane are also involved in chromatin regulation, and maintaining 
nuclear shape and integrity. SUMO is implicated in some of these essential functions, 
however, how sumoylation is regulated remains unknown. We hypothesize that SENP2 
plays a role in regulating membrane-associated functions by controlling the sumoylation 
of identified interacting proteins. 
At the inner nuclear membrane, SENP2 interacts with lamins and lamin-
associated proteins. We identified LAP2 as a substrate of SENP2, however, we have yet 
to investigate how LAP2 sumoylation and SENP2 regulation is functionally significant. 
Sumoylation is also implicated in the regulation of chromatin organization, for example, 
regulating the interactions between lamins and chromatin (Neyret-Kahn et al., 2013). 
SUMO plays an important role in orchestrating the “on” and “off” states of chromatin, 
yet again, very little is known about the regulation of this process. Finally, sumoylation is 
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also involved in regulating several ion channels, including CFTR. A defective CFTR, 
most commonly CFTRΔF508, leads to cystic fibrosis, a disease in which patients suffer 
from a build up of viscous secretions and infections by pathogenic bacteria. Both wild 
type and mutant CFTR proteins are regulated by sumoylation (Gong et al., 2016; Meng et 
al., 2017); however, the exact molecular mechanisms are not yet elucidated.  
In this appendix, we present three different attempts for studying SENP2 and 
possible membrane-associated functions. We investigated the role of SENP2 regulation at 
the inner nuclear membrane, more specifically, regulation of LAP2. Secondly, we closely 
examined the role of SENP2 regulation in chromatin organization. Finally, we 
investigated SENP2 function at the ER membrane and its role in regulating CFTR 
degradation or stability. Overall, the data presented here reveals promising avenues of 
research that could be further explored.  
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MATERIALS AND METHODS 
 
Antibodies 
Rabbit polyclonal SENP2, LAP2, and lamin B antibodies were produced as 
previously described (Chaudhary and Courvalin, 1993; Fischer et al., 2001; Goeres et al., 
2011). Remaining antibodies were obtained from the following sources: anti-GFP 
(Clontech, Mountain View, CA); anti-tubulin (Sigma-Aldrich, St. Louis, MO); and anti-
CFTR (Millipore Sigma, Burlington, MA).   
 
Plasmid constructs 
SENP2 cDNA was obtained as previously described (Zhang et al., 2002). Full 
length SENP2 was PCR amplified and cloned into pEGFP-C1 as described (Goeres et al., 
2011), and cloned into pmCherry-C1 expression vector, using standard cloning 
procedures. SENP2 NLS mutation (mNLS: R29A/R49A) was introduced using PCR 
based, site-directed mutagenesis. CFTRWT and CFTRΔF508 were cloned into pcDNA 
expression vector. Both CFTR plasmids were a generous gift from the Zeitlin lab (Johns 
Hopkins University, Baltimore, MD).  
 
Cell culture 
HeLa cells were maintained in DMEM supplemented with 10% fetal bovine 
serum. IB3-1 cells were maintained in LHC-8 without gentamicin, supplemented with 
10% fetal bovine serum. TCIS system cell lines (EGFP-LacI, I/D6+EGFP-LacI, and 
YY1-EGFP-LacI) were maintained in DMEM with high glucose, supplemented with 
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1mM sodium pyruvate, 10% fetal bovine serum, 100 U/ml penicillin-streptomycin, 2mM 
L-Glutamine, 1µg/mL puromycin, and 1mM IPTG. EGFP-LacI and YY1-EGFP-LacI 
were also supplemented with 500µg/mL hygromycin. To allow binding of EGFP-LacI to 
LacO, IPTG was removed 24-36 hours prior to visualization. All cell lines were 
incubated at 37°C and 5% CO2.   
 
Transient transfection, and RNA interference 
Cells were grown at a confluency of 50-60% for transfection with the indicated 
plasmids using Lipofectamine 2000 according to manufacturer’s protocol (Invitrogen, 
Carlsbad, CA). For RNA interference, cells were grown to 40-50% confluency and then 
transfected using RNAiMAX (Invitrogen, Carlsbad, CA). siRNA oligos were used at a 
final concentration of 25nM. siRNA oligos included the following: scramble control, 5′-
CUUCCUCUCUUUCUCUCCCUUGUGA-3; and SENP2 oligo, 5′-
GAAAGAGAGAAGUACCGAA-3′. Cells were harvested either at 24 or 48 hours post-
transfection, as indicated, for immunoblotting, or immunofluorescence microscopy.     
 
Viral transduction 
shSENP2 cloned into pLKO.1 was purchased from The RNA Consortium (TRC) 
Broad Institute (http://hitcores.bs.jhmi.edu/search_rna.php), clone ID: NM_029457.2-
1809s1c1. Control shRNA directed against firefly luciferase (5′-
CGCTGAGTACTTCGAAATGTC-3′) was obtained from the Reddy lab (Johns Hopkins 
University, Baltimore, MD). Lentivirus was produced by co-transfecting the shRNA- or 
mCherry-SENP2 plasmid, with psPAX2 (packaging plasmid) and pMD2.G (envelope 
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plasmid) into HEK 293FT cells. Virus was harvested after 48 hours, filtered, and added 
to 30-40% confluent TCIS cells and removed after 24 hours. Cells were harvested after 3-
4 days post-infection for analysis by RT-PCR and immunofluorescence microscopy. RT-
PCR was used to verify SENP2 knockdown efficiency. Reverse transcription was carried 
out using SuperScript III Reverse Transcriptase according to manufacturer’s protocol 
(Invitrogen, Carlsbad, CA).  
 
Immunoblotting, and immunofluorescence microscopy 
Immunoblot and immunofluorescence microscopy analyses were performed as 
described in the Materials and Methods section of Chapter II.  
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RESULTS AND DISCUSSION 
 
SENP2 and LAP2 
We have identified LAP2 as a substrate of SENP2 by two complementary 
approaches, BioID and SUMO capture (refer to chapter II and III). However, how SENP2 
and sumoylation are involved in regulating LAP2 functions are not known. Based on 
known functions of sumoylation, we hypothesized that SENP2 plays a role in regulating 
LAP2 localization at the inner nuclear membrane. To test this, we reduced the levels of 
SENP2 in HeLa cells by siRNA-mediated knockdown, and analyzed LAP2 localization 
and expression levels (Figure A-1). In control cells, LAP2 localized to the nuclear 
periphery and the nucleoplasm. With SENP2 knockdown, we observed a significant 
decrease in LAP2 nucleoplasmic signal, and an increased signal at the nuclear periphery 
(Figure A-1A and B). However, when we looked at LAP2 isoforms by immunoblotting, 
there was no difference in LAP2 expression levels between SENP2 knockdown and 
control cells (Figure A-1C). Therefore, the loss of signal observed by 
immunofluorescence microscopy cannot be explained by a decrease in LAP2 protein 
expression. Whether this apparent shift in LAP2 localization from the nucleoplasm to the 
nuclear membrane is directly linked to LAP2 sumoylation remains to be tested. One 
could hypothesize however, that SENP2 knockdown results in increased LAP2 
sumoylation and enhanced interactions with proteins at the inner nuclear membrane. We 
have repeated the same experiment with an overexpression of SENP2WT, however, there 
were no differences observed in LAP2 localization compared to the control (data not 
shown).  
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Thus far, there are three known LAP2 isoforms (α, β, and γ). LAP2α lacks a 
transmembrane domain and is therefore soluble, while the other two isoforms are 
anchored to the inner nuclear membrane by a single transmembrane span near the C-
terminus (Gant et al., 1999). In this experiment, we were not able to determine which 
specific LAP2 isoform is being affected by SENP2 knockdown. It is reasonable to 
suggest that membrane-associated LAP2β and LAP2γ are more likely to be regulated by 
SENP2, however, given the change in LAP2 localization from nucleoplasmic to nuclear 
membrane, we cannot rule out that SENP2 might also indirectly regulate LAP2α. One 
could hypothesize that the sumoylation of LAP2β results in the recruitment and stable 
association of LAP2α with the membrane. Our SUMO capture data implied that LAP2β 
is the specific isoform regulated by SENP2, based on the size of LAP2β and the higher 
molecular weight band observed with SENP2CS pull-down (refer to Chapter III, Figure 
III-6C). The anti-LAP2 antibody used in this experiment detected all three isoforms, and 
although there was no change in LAP2 expression levels, the disappearance of the 
nucleoplasmic signal and change in LAP2 localization was intriguing. Therefore, as a 
future direction, it would be interesting to decipher which particular isoform is being 
affected by SENP2 knockdown by using isoform-specific antibodies.    
In addition to investigating each LAP2 isoform, another future direction would be 
to test SENP2 effect on LAP2-specific functions. LAP2 plays a role in mediating 
chromatin-membrane attachment, and nuclear lamina assembly, but whether sumoylation 
regulates those functions is unknown (Gant et al., 1999). In summary, our preliminary 
findings support a role for SENP2 and sumoylation in regulating LAP2 localization at the 
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inner nuclear membrane. Understanding the molecular mechanisms and functional 
significance of this regulation will require further investigation.  
 
SENP2 and chromatin organization 
SENP2 uniquely interacts with the inner nuclear membrane, where it directly 
associates with the nuclear lamina and lamin-associated proteins. Lamin A and lamin B 
were among our significant BioID hits, and both are known to be sumoylated. Defects in 
their sumoylation are implicated in lamin-associated diseases (laminopathies) (Sarge and 
Park-Sarge, 2011; Simon et al., 2013). What regulates the sumoylation of lamins, 
however, has not been investigated. Given our data on SENP2 localization and 
interactions with lamins, we hypothesize that SENP2 plays a role in the regulation of 
their sumoylation and associated functions, a major one being chromatin organization. 
Sumoylation is also strongly tied with transcriptional repression, but the mechanisms still 
await full characterization (Neyret-Kahn et al., 2013). We hypothesize that SENP2, 
through effects on sumoylation of specific proteins at the inner nuclear membrane, can 
coordinate the association of chromatin with the nuclear lamina, and therefore indirectly 
regulate gene expression. To test the role of SENP2 in regulating chromatin organization 
at the inner nuclear membrane and lamina, we turned to the tagged chromosomal 
insertion site (TCIS) system (Figure A-2) (Harr et al., 2015). The TCIS system utilizes 
three cell lines to quantitatively monitor the localization and association of a specific, 
EGFP-tagged, lamin-associated sequence (LAS) of chromatin to the nuclear 
lamina/periphery (detailed description of the TCIS system is provided in the figure 
legend of Figure A-2). In control cells (EGFP-LacI), the EGFP-tagged chromatin is not 
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associated with the nuclear lamina and therefore is scored as “central” by fluorescence 
microscopy (Figure A-2, A and D). In contrast, in I/D6+EGFP-LacI cells, EGFP-tagged 
chromatin associates with the nuclear lamina due to the presence of D6 – a known LAS – 
therefore, the signal of D6 overlapping with the nuclear periphery is scored as 
“peripheral” by fluorescence microscopy (Figure A-2, B and D). Similarly, EGFP-tagged 
chromatin associates with the nuclear periphery in YY1-EGFP-LacI cell line harboring 
the Ying-Yang 1 (YY1) protein, which also directs chromatin association with the 
nuclear lamina (Figure A-2C). We used the three TCIS system cell lines to overexpress 
or knockdown SENP2 and then monitor the localization of EGFP-tagged chromatin by 
fluorescence microscopy. We hypothesized that changes in SENP2 expression levels 
would affect the recruitment of chromatin domains to the nuclear periphery (Figure A-2, 
B and C).   
We first used RNAi to knockdown SENP2 expression and assessed effects on 
chromatin localization in the three TCIS cell lines. Knockdown efficiency was verified 
using RT-PCR (data not shown). In EGFP-LacI control cells, the tagged chromatin was 
centrally located in 80% of cells, and this was unaffected by SENP2 depletion (Figure A-
3). I/D6+EGFP-LacI and YY1-EGFP-LacI cell lines exhibited 80% peripheral signal, and 
this localization was also not significantly different between control and SENP2 
knockdown conditions (Figure A-3). We next overexpressed mCherry-SENP2 and only 
scored cells with a mCherry signal. Again, we observed no significant difference in 
chromatin localization in EGFG-LacI control cells (Figure A-4). In contrast, SENP2 
overexpression caused an ~15% decrease in peripherally associated chromatin in 
I/D6+EGFP-LacI expressing cells (Figure A-4). This result suggests that SENP2 may 
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play an active role in limiting SUMO-dependent chromatin recruitment and repression at 
the inner nuclear membrane, and is consistent with known roles for sumoylation in 
chromatin repression. One might argue that a 15% decrease in chromatin association with 
the nuclear periphery is not significant, however, earlier studies have shown that a slight 
15-20% change in chromatin organization is sufficient to have measurable effects on 
gene activation or repression (Harr et al., 2015). Overall, our overexpression results 
provide evidence for a role for SENP2 in regulating chromatin localization and 
organization at the inner nuclear membrane. Further studies are needed to fully explore 
this finding and implications for control of gene expression.  
Using our experimental design, it was challenging to study whether SENP2 
positively affects chromatin association with the nuclear periphery since the cell lines 
used were harboring LASs that would target chromatin to the nuclear periphery, and 
therefore, more than 80-90% of the chromatin was already associated with the lamina. 
Electron microscopy to look at chromatin organization, or looking at the levels of specific 
heterochromatin and euchromatin markers might present alternative methods to further 
investigate SENP2 regulation.     
 
SENP2 and CFTR 
In another attempt to investigate the role of SENP2 at intracellular membranes, 
we have focused on CFTR as a promising candidate substrate. CFTR functions as a 
chloride ion channel at the plasma membrane. The folding, packaging and export of 
CFTR from the ER to the plasma membrane is highly regulated by many 
posttranslational modifications, one of which is sumoylation (Gong et al., 2016). Since 
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SENP2 is associated with intracellular membranes, we hypothesized that SENP2 might 
play a role in regulating CFTR sumoylation. Both mature and immature forms of CFTR 
are regulated by SUMO. Evidence suggests that the sumoylation of CFTRΔF508, the most 
common CFTR mutation associated with cystic fibrosis, blocks its export to the plasma 
membrane by targeting it for degradation (Ahner et al., 2013). Here, we hypothesize that 
the overexpression of SENP2 and the subsequent de-conjugation of SUMO would delay 
the degradation of the mutant protein, giving it time for proper folding and subsequent 
export from the ER to the plasma membrane (Figure A-5A). To test this, we used IB3-1 
cells derived from patients with cystic fibrosis carrying the CFTRΔF508 mutation, and we 
transiently overexpressed GFP-SENP2. To assess whether the mutant protein was 
rescued, we looked at the abundance of the three different molecular weight forms of 
CFTR protein: 127kDa (A band), 131kDa (B band), and 160kDa (C band). Bands A, B, 
and C represent different glycoforms of CFTR: the non-glycosylated, the core 
glycosylated, and the mature CFTR with complex glycosylation, respectively (O'Riordan 
et al., 2000). The overexpression of CFTRWT served as a positive control. The most 
abundant form of CFTRWT is the mature, C band (Figure A-5B, first lane). In contrast, 
CFTRΔF508 is predominantly synthesized as A and B bands (Figure A-5B, second lane). In 
cells expressing CFTRΔF508, with or without SENP2WT, A and B bands were observed, 
but no C band (Figure A-5B). This indicates that SENP2WT had no effect on the maturity 
of the mutant protein. We also expressed SENP2mNLS to enrich for SENP2 at the ER 
membrane, but again, there was no effect on CFTR maturation (Figure A-5B). This 
indicates that simply overexpressing SENP2 does not rescue the mutant CFTRΔF508 from 
degradation, and perhaps the role of sumoylation and potentially SENP2 is more complex 
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and requires further investigation. It is reasonable to suggest that SENP2 might not 
recognize sumoylated CFTR, and that SENP2 substrate specificity extends beyond its 
association with membranes.  
CFTR has a complex folding pattern that involves a variety of post-translational 
modifications including sumoylation, ubiquitination, phosphorylation and glycosylation. 
It is the crosstalk between these different modifications that could determine the fate of 
the protein (Ahner et al., 2013). Multiple lysine residues in both wild type and mutant 
CFTR are sumoylated and ubiquitinated at different subcellular locations, including the 
ER, Golgi and plasma membrane (Ahner et al., 2013; Lee et al., 2014). Overall, the 
complexity of CFTR regulation makes it challenging to determine the specific roles of 
SENP2 without considering the crosstalk between those various modifications. More 
specifically, SUMO and ubiquitin modifications can result in unique “codes” that 
determine whether the protein is targeted to degradation or is stabilized at the plasma 
membrane (Figure A-6). Therefore, more detailed analyses are required to untangle 
SUMO-specific regulatory functions. 
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Figure A-1. Effect of SENP2 knockdown on LAP2 localization and expression levels. 
HeLa cells were transfected with scramble (control) or SENP2-specific siRNA oligos 
then harvested after 48 hours. (A) Cells were stained with anti-LAP2 antibody and 
analyzed by indirect immunofluorescence microscopy. Control cells show the typical 
localization of LAP2, around the nuclear rim and in the nucleoplasm. SENP2 knockdown 
caused a general loss of LAP2 signal with a concentrated signal around the nuclear 
periphery. Scale bar = 5 µm. (B) Quantification of LAP2 nucleoplasmic signal and 
nuclear rim signal, based on immunofluorescence intensity. As observed in part A, there 
is a decrease in overall signal but an increase in nuclear rim staining from 6% to 30%. (C) 
Immunoblot analysis using anti-LAP2 and anti-SENP2 antibodies. Anti-LAP2 antibody 
recognizes at least three LAP2 isoforms: α, β, and γ. No difference was observed in the 
expression levels of LAP2 between control and SENP2 knockdown cells. Anti-SENP2 













Figure A-2. Schematic diagram of the three TCIS system cell lines. 3T3 derived 
C57BL/6 fibroblast cell lines stably expressing EGFP-LacI or YY1-EGFP-LacI with 
randomly co-integrated bacterial artificial chromosomes (BACs) and hygromycin-
selectable LacO arrays were used to study the effect of SENP2 knockdown or 
overexpression on chromatin organization. LacO arrays serve as docking sites for EGFP-
LacI enabling quick identification by fluorescence microscopy.  (A) Control cell line 
stably expressing EGFP-LacI (designated in green and blue) and integrated BACs with 
LacO (designated in orange). LacI binds to LacO, and GFP provides the localization of 
that specific chromatin region. In control, the signal is mostly concentrated in the 
nucleoplasm and therefore scored as “central”. Upon SENP2 overexpression or 
knockdown, we expect no change in the localization. (B) I/D6+EGFP-LacI cell line 
contains a BAC carrying a lamin-associated sequence (LAS) containing the gene Ikaros 
(designated in yellow and labeled “I/D6”). I/D6 sequence targets DNA to the periphery of 
the nucleus, to associate with the nuclear lamina, and hence the signal is scored as 
“peripheral” by fluorescence microscopy. Again, stably expressed EGFP-LacI assists in 
visualization. We hypothesize that SENP2 might directly affect chromatin organization 
by altering the signal from “peripheral” to “central”. (C) YY1-EGFP-LacI cell line stably 
expressing YY1 fused to EGFP-LacI (designated with a yellow circle). YY1 interacts 
with chromatin and indirectly targets DNA to the nuclear periphery, hence signal is 
scored “peripheral”. In this case, we hypothesize that SENP2 may indirectly affect 
chromatin organization and result in changing the localization from peripheral to central. 
Abbreviations used: INM = inner nuclear membrane; ONM = outer nuclear membrane; 
K/D = knockdown; OE = overexpression. (D) Representative images for all 3 cell lines 
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showing the difference between a central and peripheral signal for scoring purposes. 
Arrows indicate GFP signal scored. An overlap between EGFP-LacI/LacO focus and 























Figure A-3. Effect of SENP2 knockdown on chromatin organization. Cells were treated 
with lentivirus containing SENP2 shRNA or luciferase shRNA (control) for 3 days then 
harvested and analyzed by indirect immunofluorescence microscopy. SENP2 knockdown 
efficiency was verified at the mRNA level by PCR. (A) Cells were stained with anti-
Lamin B antibody to stain the periphery of the nucleus. The GFP signal (indicated with 
white arrows) represents the EGFP-LacI/LacO focus. Signal for EGFP-LacI cells was 
peripheral as expected and no changes were observed with SENP2 knockdown. 
I/D6+EGFP-LacI and YY1-EGFP-LacI cell lines exhibited an 80% peripheral signal, 
with no difference observed between control cells and SENP2 knockdown cells, 
indicating that SENP2 knockdown has no effect on chromatin organization. (B) 















Figure A-4. Effect of SENP2 overexpression on chromatin organization. Cells were 
transiently transfected with mCherry alone or mCherry-SENP2 for 24 hours. Cells were 
then harvested and analyzed by indirect immunofluorescence microscopy. To stain the 
nuclear periphery, cells were stained with anti-Lamin B antibody. (A) Quantification of 
peripheral foci from the two transfected cell lines: EGFP-LacI (control) and I/D6+EGFP-
LacI. No differences were observed between the empty vector and SENP2 
overexpression in the control cell line. However, a higher number of peripheral foci was 
observed in the control cell line for both conditions, which could be an artifact due to 
transfection. SENP2 knockdown in the I/D6+EGFP-LacI cell line exhibited a 15% 
decrease in the number of peripheral foci compared to control, indicating that SENP2 
knockdown has an effect on chromatin association with the nuclear lamina. Even though 
the control cell line exhibited a higher number of peripheral foci, the trends still hold true. 
“n” indicates the number of cells counted in each condition. (B) Percentages of peripheral 












Figure A-5. Effect of SENP2 overexpression on CFTRΔF508 stability. (A) Schematic 
diagram representing our model for the effect of SENP2 overexpression. The 
sumoylation of CFTRΔF508 targets the protein for proteasomal degradation. We 
hypothesize that SENP2 overexpression and the subsequent de-conjugation of SUMO 
from CFTRΔF508 can rescue the protein from degradation and target it to the plasma 
membrane. (B) IB3-1 cells were transiently transfected with CFTRWT or CFTRΔF508, with 
or without co-transfection with GFP-SENP2WT or GFP-SENP2mNLS. Cells were harvested 
48 hours post-transfection and analyzed by immunoblotting. Expression of CFTRWT or 
CFTRΔF508 alone was used as positive and negative controls, respectively. With wild type, 
the C band is the major form present at the plasma membrane, which represents the 
mature form of the channel with complex glycosylation. In contrast, CFTRΔF508 is 
synthesized predominantly as bands A and B, representing immature, non-glycosylated or 
core glycosylated forms, respectively. Co-expression of SENP2WT or SENP2mNLS had no 
effect on CFTRΔF508 maturation or stability, since no C band was observed. Anti-GFP 
antibody was used to detect the expression levels of GFP-SENP2 constructs. Tubulin was 









Figure A-6. Schematic model showing the crosstalk between CFTR%F508 sumoylation and 
ubiquitination. Modification of different lysine residues results in a unique “code” that 
determines the fate of CFTR%F508. Depending on this crosstalk between sumoylation and 
ubiquitination, mutant CFTR may be targeted to degradation, via the proteasomal or the 


























There is growing evidence for the role of sumoylation outside the nucleus. From 
glucose transport and ion channel regulation at the plasma membrane, to mitochondrial 
fission and fusion, SUMO touches multiple cellular functions in the cytoplasm and at 
intracellular membranes. How sumoylation is regulated within these different subcellular 
domains however, remains a question in the field. This thesis focused on understanding 
how sumoylation is regulated at intracellular membranes, a relatively new domain being 
explored. We found that the SUMO protease SENP2 interacts with intracellular 
membranes via a unique N-terminal targeting signal, an amphipathic α-helix. We showed 
that SENP2-membrane interaction is regulated by the nuclear import machinery, more 
specifically, Kap-α. Furthermore, we identified SENP2 interacting binding partners by 
BioID, and found that SENP2 interacts with a specific subset of membrane-associated 
proteins at the ER, Golgi, and inner nuclear membranes. We also developed a new 
method, called “SUMO capture”, to identify SENP2 substrates. Combining BioID and 
SUMO capture data, we identified LAP2 as a SUMO-modified SENP2 substrate. Finally, 
we initiated studies to investigate functional roles for SENP2 at membranes, and in 
particular its effects on LAP2 and chromatin association with the inner nuclear 
membrane, and ion channel maturation in the ER. Overall, we have elucidated a novel 
mechanism for regulating SENP2 via a unique N-terminal membrane-targeting signal, 





In Chapter II, we provided in vivo and in vitro evidence for SENP2-membrane 
interaction. We found that Kap-α binding regulates this interaction, where it impedes 
SENP2 amphipathic α-helix from associating with membranes in the cytoplasm. This 
intriguing finding begs us to ask the question: Do mechanisms exist to regulate SENP2 
interactions with Kap-α, thereby modulating cytosolic membrane binding? Given our 
evidence that SENP2 interacts with ER and Golgi, there must be other mechanisms by 
which the amphipathic α-helix is still capable of interacting with membranes in the 
cytoplasm, even with the presence of Kap-α. To study this, it would be important to first 
pursue structural analyses of SENP2 in complex with Kap-α, in order to understand the 
molecular basis of Kap-α interaction. Secondly, there are predicted SENP2 isoforms 
lacking the amphipathic α-helix or the nuclear localization signal that remain 
uncharacterized (Nishida et al., 2001). These isoforms are expected to be differentially 
targeted to membranes, and therefore it will be important to identify and characterize 
these and other isoforms more carefully. It is also possible that different cell types may 
express different SENP2 isoforms based on specific cellular functions. Finally, other 
post-translational modifications of SENP2 might play a role in its regulation. SENP2 is 
phosphorylated and sumoylated (Bailey and O'Hare, 2004), however, it is not yet known 
how these modifications affect SENP2 localization or function, and they should also be 





SENP2 SUBSTRATES AND FUNCTIONAL SIGNIFICANCE 
We developed a method to capture and identify sumoylated SENP2 substrates as 
outlined in Chapter III. It is anticipated that utilizing the SUMO capture approach in 
combination with mass spectrometry will provide comprehensive catalogs of SENP2 
substrates and related functions. In the appendix, we described efforts to explore the 
functional significance for SENP2 at membranes. We provided insights on SENP2 
function in relation to LAP2 regulation, chromatin organization, as well as CFTR 
regulation. We found that the signal of LAP2 localization changes from nucleoplasmic to 
peripheral upon SENP2 knockdown. One of the immediate future directions is to study 
SENP2 effects on specific LAP2 isoforms by using isoform-specific antibodies. Once we 
determine which LAP2 isoform is regulated by SENP2, we can investigate downstream 
functional consequences of SENP2 regulation, including changes in localization, protein 
expression, and utilizing RT-qPCR (real time-quantitative PCR) for studying changes in 
gene expression of LAP2-specific transcription factors. Besides the effect on LAP2 
localization, changes in SENP2 levels also changed the localization of chromatin from 
the periphery to the nucleoplasm. In the future, we hope to look more closely at the effect 
of SENP2 on chromatin organization by utilizing electron microscopy techniques. 
Finally, although we did not find a direct link between SENP2 regulation and CFTR in 
our experiments, we are eager to decipher the molecular mechanism behind the 
regulation of CFTR sumoylation and its implication in cystic fibrosis. A global approach 
to study CFTR sumoylation in the context of disease is to turn to animal models. There 
are mice models of cystic fibrosis that are widely used for experimental therapies (Wilke 
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et al., 2011). It would be interesting to knock-in SENP2I8D in this mouse background to 
determine the role of SENP2-membrane interaction on disease development.  
Given that SENP2 shares the common feature of having an amphipathic α-helix 
with many nucleoporins, and localizes to NPCs, it would be interesting to investigate 
whether SENP2 plays an important role in NPC assembly, especially after nuclear 
envelope breakdown (NEBD). During NEBD, specific nucleoporins are thought to induce 
the formation of membranous vesicles that carry and stabilize some membrane-associated 
proteins until cell division is complete (Prunuske et al., 2006; Alber et al., 2007; Doucet 
and Hetzer, 2010; Doucet et al., 2010; Drin and Antonny, 2010; Meszaros et al., 2015; 
Souquet and Doye, 2015). Those nucleoporins are also sumoylated, and it is possible that 
SENP2, with its ability to associate with membranes, maintains the regulation of 
nucleoporins associated with membranous vesicles and assists in nuclear envelope and 
NPC re-assembly (Chow et al., 2012; Chow et al., 2014). To study this, we could turn to 
live-cell imaging. Monitoring the events of pre- and post-NEBD under SENP2 
knockdown and overexpression conditions, and tracking specific nucleoporins involved 
in NPC and nuclear envelope re-assembly will provide insight on the role of SENP2 in 
regulating this process.  
Besides inner nuclear membrane-associated proteins, BioID analysis revealed that 
SENP2 uniquely interacts with ER and Golgi proteins. When clustered into functional 
groups, the majority of these proteins are associated with ER-to-Golgi trafficking, 
implying that SENP2 might have a role in regulating vesicular transport. Furthermore, it 
was intriguing to find that SENP2 interacts with 8 out of 10 subunits of the EMC 
complex (refer to Chapter II). The EMC complex is involved in cellular response to ER 
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stress, ERAD, and lipid homeostasis (Jonikas et al., 2009; Christianson et al., 2011; 
Richard et al., 2013; Lahiri et al., 2014; Satoh et al., 2015; Wideman, 2015). We are 
interested in investigating whether SENP2 is involved in regulating EMC complex 
assembly, and its associated functions. Future studies will focus on determining the 
localization and expression of each EMC subunit in the context of SENP2 knockdown 
and overexpression. Later on, we would like to decipher the effect of EMC complex 
sumoylation on the ER stress response by treating cells with different ER stress inducers 
and determining the effects on overall sumoylation of the EMC complex, and its 
subsequent functions. Interestingly, the EMC complex also facilitates efficient insertion 
of tail-anchored proteins into ER membranes (Guna et al., 2018). Whether the EMC 
complex itself facilitates SENP2 binding to the ER membrane is worth pursuing. This 
could be further studied by knocking down EMC subunits and looking at the localization 
of SENP2. As mentioned earlier, a SENP2I8D knock-in mouse model would also be 
helpful to look at the physiological relevance of SENP2-membrane association in relation 
to EMC-associated functions.  
 
IS MEMBRANE ASSOCIATION REGULATORY? 
In this thesis, we have described SENP2-membrane targeting as a way to regulate 
sumoylation at intracellular membranes, subsequently regulating the many membrane-
associated functions. Together with other published findings, there is a plethora of 
evidence demonstrating SUMO-mediated regulation at membranes and leading us to 
propose that SENP2 serves as the master regulator within that particular domain. 
However, it is also important to consider the possibility that SENP2 evolved to contain a 
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membrane-targeting signal as a way to restrict its activity and the de-conjugation of 
soluble nucleoplasmic and cytoplasmic proteins. In other words, membrane targeting 
could function to both restrict and promote specific SENP2-substrate interactions. In fact, 
there is evidence showing that NPC-association of the SUMO isopeptidase Ulp1 in yeast 
has an essential role in preventing de-conjugation of soluble sumoylated proteins (Li and 
Hochstrasser, 2003). It would be interesting to fully investigate whether such mechanism 
of regulation also exists in mammalian cells. Again, a SENP2I8D knock-in mouse model 
can be utilized to determine the physiological effects of losing SENP2-membrane 
association. Overall, the significance of SENP2-membrane interaction and how it relates 
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